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Abstract 
Epithelial ovarian cancer is the fourth leading cause of cancer-related death in 
women and accounts for the highest mortality rate of all gynecological 
malignancies. In fact, the cure rates have remained unchanged over the last 20 
years though radical surgery, radiation therapy, chemotherapy and targeted 
therapy have improved survival times. Thus, additional treatment options in 
ovarian cancer therapy are urgently needed. It is documented that fatty acid 
synthase (FASN) is overexpressed in more than 80% of ovarian carcinomas, 
whereas in normal cells FASN is mostly absent. Therefore, FASN represents a 
very promising molecular anticancer target. FASN has been identified as an 
independent prognostic factor for clinical outcome in ovarian cancer and 
increased expression of FASN in ovarian neoplasms predicts shorter survival. 
Natural and synthetic compounds have been described that inhibit FASN activity 
very efficiently. Moreover, inhibition of FASN causes growth arrest in breast 
cancer and delays disease progression of ovarian carcinomas in xenograft 
models. Up to date, a conclusive molecular explanation of the anti-proliferative 
and death-promoting effect of FASN inhibitors is still missing. This work is the 
first report about epigenetically modulating activity of FASN inhibition. Using the 
FASN inhibitor C75, we could show a demethylation of the hypermethylated 
death associated protein (DAP) kinase promoter region followed by enhanced 
DAP kinase mRNA transcription in the ovarian cancer cell line A2780. The 
expression of epigenetically active enzymes was also found to be modulated by 
the FASN blocking drug C75. We further pointed out several effects of FASN 
inhibition including enhanced ubiquitin-dependent protein degradation and 
downregulation of PI3K signaling molecules. Moreover, we could confirm anti-
proliferative and apoptosis-inducing actions induced by FASN inhibition in 
Affimetrix microarray mRNA expression analyses. 
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Zusammenfassung 
Epitheliales Ovarialkarzinom ist die vierthäufigste Todesursache bei Frauen 
aufgrund von Krebs und hat die höchste Mortalitätsrate von allen 
gynäkologischen Erkrankungen. In den letzten 20 Jahren blieb die Heilungsrate 
von Ovarialkarzinomen weitläufig unverändert, allerdings konnte der 
Überlebenszeitraum durch chirurgische Operation, Strahlentherapie, 
Chemotherapie und gezielter molekularen Therapie verlängert werden. Deshalb 
werden zusätzliche Behandlungsmethoden in der Ovarialkarzinom-Therapie 
dringend gebraucht. Das Enzym Fettsäuresynthase (FASN) wird in über 80% der 
Ovarialkarzinome über-exprimiert, wohingegen dieses Enzym in normalen Zellen 
meist gar nicht exprimiert wird. Aufgrund dieser Tatsache repräsentiert FASN ein 
vielversprechendes molekulares Ziel für eine Therapie gegen Krebs. FASN ist 
außerdem ein unabhängiger prognostischer Faktor für den klinischen Ausgang 
bei Ovarialkarzinomen und sagt einen kürzeren Überlebenszeitraum bei 
ovarialer Neoplasie voraus. Es wurden bereits einige natürliche und synthetische 
Substanzen beschrieben, die die FASN-Aktivität sehr effizient inhibieren. 
Darüber hinaus konnte gezeigt werden, dass die Inhibierung von FASN zu einem 
Wachstumsarrest von Mammakarzinomen führt und das Fortschreiten von 
Ovarialkarzinomen in Xenograft Modellen verzögert wird. Bis jetzt konnte man 
noch keine schlüssige molekulare Erklärung für die anti-proliferativen und 
Apoptose-induzierenden Effekte von FASN-Blockern finden. Diese Arbeit 
berichtet erstmalig über die epigenetisch modulierenden Aktivitäten der FASN-
Inhibierung. Unter Verwendung des FASN-Inhibitors C75 konnte eine 
Demethylierung der hypermethylierten „death associated protein“ (DAPK) 
Promotor Region und eine anschließende vermehrte DAPK mRNA Transkription 
in der ovarialen Karziomzelllinie A2780 gezeigt werden. Darüber hinaus wurde in 
dieser Arbeit auch eine Modulierung der Expression von epigenetisch aktiven 
Enzymen durch FASN-Inhibierung beschrieben. Zudem wurden mehrere 
zusätzliche Effekte der FASN-Blockade herausgearbeitet, die unter anderem 
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Ubiquitin-abhängige Protein Degradation und Aktivitätshemmung der PI3K/AKT 
Signal Moleküle beinhalten. Abschließend konnten die anti-proliferativen und 
Apoptose-induzierenden Effekte der FASN-Inhibierung durch Affimetrix 
Microarray mRNA Expressionsanalyse bestätigt werden. 
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1 Introduction 
1.1 Definitions 
The ovaries contain three kinds of tissue. First, epithelial cells which cover the 
ovary, second, germ cells which produce the oocyte inside the ovary, and third, 
stromal cells which produce most of the female hormones such as estrogen and 
progesterone. The tumors in the ovary are named for the kinds of cells the tumor 
started from. Therefore, there are three main types of ovarian tumors. The 
epithelial ovarian tumor is the most common type of ovarian tumors and can be 
divided into three sub-groups describing the malignancy of the tumor. The 
benign epithelial tumor does not spread whereas the epithelial ovarian tumors of 
low malignant potential (LMP tumors) only spreads slowly. This kind of epithelial 
ovarian tumor is also known as borderline tumor, which cells do not have 
cancerous morphology and mostly affects women at a younger age. 
Approximately nine out of ten ovarian carcinomas are epithelial ovarian cancers 
and the cell line A2780 that is used for several experiments in this work was also 
isolated from this kind of ovarian cancer. For the sake of completeness, it should 
be mentioned that also germ cell tumors such as teratoma, dysgerminoma, 
endodermal sinus tumor or choriocarcinoma can occur. Most of the germ line 
tumors are not cancerous. Stromal tumors can be either benign such as 
thecomas and fibromas or cancerous such as granulose cell tumor, granulose-
theka tumors or sertoli-leydig cell tumors. More than fifty percent of the women 
suffering from stromal tumors are over fifty year old. Furthermore, some rare 
cancers show similar symptoms to epithelial ovarian cancer. These are the 
primary peritoneal carcinoma, which starts outside the ovaries and grows from 
the cells that line the pelvis and the abdomen and second the fallopian tube 
cancer which starts from the tube that carries the oocyte from the ovary to the 
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uterus. Moreover, ovarian cysts also show similar symptoms to epithelial ovarian 
cancer. Ovarian cysts collect fluid inside an ovary, which is often absorbed 
without any treatment (American Cancer Society, 2009).  
1.2 Incidence and Mortality Rate of Ovarian Cancer 
Epithelial ovarian cancer is the fourth leading cause of cancer-related death in 
women and accounts for the highest mortality rate of all gynecological 
malignancies (Brewer et al., 2003). Undisturbed growth of the tumor in the 
peritoneal cavity where the ovaries are localized without any symptoms often 
gives reasons for poor prognosis of epithelial ovarian carcinoma. Moreover, the 
detection of ovarian cancer at an early and curable state is very difficult due to 
the asymptomatic appearance of this disease (Cannistra et al., 2004). The 
overall prognosis of the 5-year survival is less than 30%, whereas 70% of these 
tumors are diagnosed with metastases. 90% of stage IA tumors and 70% of 
stage II tumors can be cured by current treatment actions, but the cure rate 
decreases below 30% for tumor stage III and IV (Brewer et al., 2003). In fact the 
cure rates have remained unchanged the last 20 years though radical surgery, 
radiation therapy, chemotherapy and targeted therapy have improved survival 
times (Brewer  et al., 2003).  
1.3 Epidemiology and High-Risk Population of Ovarian 
Cancer 
Ovarian surface epithelial cells are normally quiescent but proliferate after 
ovulation to repair the epithelial wound caused by the release of an oocyte from 
a mature follicle. Growth factors and high estrogen may provide stimuli for 
proliferation and wound healing (Brewer et al., 2003). Thus, larger number of 
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ovulatory cycles caused by fertility drugs or early age at menarche and late age 
at menopause increase the risk of ovarian cancer. On the contrary, suppressed 
ovulation caused by pregnancy, breast feeding and birth control pill is associated 
with decreased risk of developing epithelial ovarian cancer. Moreover, BRCA1 
mutation is linked to an approximately 40-60% risk of developing ovarian cancer 
and an 85% risk of developing breast cancer. Advanced age is another risk 
factor for developing epithelial ovarian cancer (Brewer et al., 2003). 
1.4 Staging 
Staging is the process of finding out how far the cancer has spread and 
influences the treatment. The TNM system is used to describe the cancer in 
terms of the extent of the tumor (T), whether or not it has spread to the nearby 
lymph nodes (N), and whether it has metastasized to organs farther away (M). 
When the TNM groups have been described, the information is combined and 
assigned to a number from 1 to 4 (American Cancer Society, 2009). 
 
Tumors 
Primary tumors (T) are classified according to the following categories:  
T1: The tumor is limited to one or both ovaries. 
T1a: The tumor is limited to one ovary. The capsule of the tumor is intact, there 
is no tumor on the ovarian surface, and there are no ovarian cancer cells in 
ascites or peritoneal lavage. 
T1b: The tumor is limited to both ovaries. The capsule is intact, there is no tumor 
on the ovarian surface, and there are no ovarian cancer cells in ascites or 
peritoneal lavage. 
T1c: The tumor is limited to one or both ovaries with any of the following: 
ruptured capsule, tumor on ovarian surface, or cancer cells in the ascites or 
peritoneal lavage. 
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T2: The tumor involves one or both ovaries and has spread into the pelvis. 
T2a: The tumor has spread and/or attaches to the uterus and/or fallopian tubes. 
There are no ovarian cancer cells in ascites or peritoneal lavage. 
T2b: The tumor has spread to other pelvic tissues. There are no cancer cells in 
ascites or peritoneal lavage. 
T2c: The tumor has spread to pelvic tissues, with ovarian cancer cells in ascites 
or peritoneal lavage. 
T3: The tumor involves one or both ovaries, with microscopically confirmed 
peritoneal metastasis outside the pelvis and/or metastasis to regional lymph 
node(s). 
T3a: Microscopic peritoneal metastasis beyond the pelvis. 
T3b: Macroscopic peritoneal metastasis beyond the pelvis, 2 cm or less in 
greatest dimension. 
T3c: Peritoneal metastasis beyond the pelvis, more than 2 cm in greatest 
dimension. 
 
Nodes 
The regional lymph nodes (N) are classified according to the following 
categories: 
N0: The regional lymph nodes contain no metastases. 
N1: There is evidence of lymph node metastasis.  
 
Metastasis 
The state of metastasis (M) is classified according to the following categories:  
M0: There are no distant metastases found. 
M1: Distant metastases are present.  
 
Stage Grouping 
The four basic stage groupings within the TNM system:  
Stage I: The cancer is contained within the ovaries 
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Stage Ia: T1a, N0, M0 
Stage Ib: T1b, N0, M0 
Stage Ic: T1c, N0, M0  
Stage II: The cancer is in one or both ovaries and has spread to other organs in 
the pelvis such as the bladder, colon, rectum, or uterus 
Stage IIa: T2a, N0, M0  
Stage IIb: T2b, N0, M0 
Stage IIc: T2c, N0, M0  
Stage III: The cancer is in one or both ovaries and has spread to one or both of 
the following: the lining of the abdomen or the lymph nodes.  
Stage IIIa: T3a, N0, M0  
Stage IIIb: T3b, N0, M0  
Stage IIIc: T3c, N0, M0, or T(any), N1, M0  
Stage IV: This is the most advanced stage. The cancer has spread from one or 
both ovaries to distant organs, such as the liver or lungs, or there may be ovarian 
cancer cells in the fluid around the lungs.  
Stage IV: T(any), N(any), M1  
(American Cancer Society, 2009; Oncologychannel, 2009) 
1.5 Treatment Options in Ovarian Cancer 
1.5.1 Surgery 
Surgery is usually performed to remove as much of the tumor tissue as possible. 
The tumor, lymph nodes in the abdomen, lymph nodes in the pelvis, abdominal 
fluids, uterus, both ovaries, both fallopian tubes and the omentum are also 
analyzed by a gynecologic oncologist to stage the cancer. Depending on the 
stage of the tumor the appropriate treatment is chosen (American Cancer 
Society, 2009).  
 Introduction 
 6 
1.5.2 First-line Therapy 
Most patients suffering from advanced ovarian cancer are not curable by surgery 
alone. Therefore, chemotherapy represents an essential method of treatment. 
Ovarian cancers in general are seen as chemotherapy-sensitive tumors because 
approximately 75% of the patients response to an initial treatment with platinum-
containing drugs cisplatin and carboplatin either used alone or in combination 
with the taxane-containing drug paclitaxel. The treatment with platin-
combinations provides longer survival rates than without platin or platin 
monotherapy. However, in 80-85% of the patients the tumors become resistant. 
If the duration of remission is longer than 6 months the tumor is considered as 
platinum-sensitive and the same drugs are used in second-line therapy as in 
first-line therapy. 25% of these patients show response to this kind of second-line 
therapy. Patients who have a shorter duration of remission than 6 months after 
first-line therapy have very poor prognosis (Kelland et al., 2005). 
1.5.3 Second-line Therapy 
As many tumors become resistant to the drugs of the first-line therapy, 
doxorubicin, topotecan, hexamethylmelamine, gemcitabine or docetaxel several 
other drugs are used for the second-line therapy (Kelland et al., 2005).  
1.5.4 Radiation Therapy 
Radiation therapy used high energy x-rays to reduce ovarian cancer cells and to 
shrink the tumor in its size. This kind of treatment may be executed additionally 
and is only rarely used as the main treatment for ovarian cancer (American 
Cancer Society, 2009).  
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1.5.5 Targeted Therapies 
Because of the resistance of many tumors to cytotoxic agents used in 
chemotherapy additional treatment options in ovarian cancer therapy are 
urgently needed. 
1.5.5.1 Monoclonal Antibodies 
There are several drugs that selectively recognize proteins or receptors of the 
ovarian tumor cells. For example, intraperitoneal administration of cisplatin- or 
radio-labelled monoclonal antibodies are currently exploited in clinical trials. The 
advantage of (radio-) immunotherapy is the possibility of regional administration 
and thereby limiting systemic side-effects. Furthermore, monoclonal antibodies 
targeting the ovarian carcinoma biomarker CA-125 are already tested (Kelland et 
al., 2005). Monoclonal antibodies binding to EGFR (cetuximab) or to the ErbB2 
(trastuzumab, pertuzumab) are reported to improve ovarian cancer treatment 
only in combination with standard cytotoxic agents (docetaxel) and may be 
considered for clinical trials (Bijman et al., 2009). 
1.5.5.2 Small Molecules 
Several small molecules have been designed to inhibit cancer specific pathways. 
Therefore, agents targeting drug resistance mechanisms or drugs that disrupt 
the cancerous angiogenesis are being developed. Furthermore, tumor specific 
enhanced cell proliferation and survival pathways can be blocked by small 
molecules inhibiting phosphorylation and activation of responsible kinases. 
Concerning this strategy, agents targeting EGFR family members, K-Ras 
inhibitors and PI3K/Akt/mTOR inhibitors are already at clinical level (Kelland et 
al., 2005). 
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1.6 Frequent Molecular Aberrations in Ovarian Cancer 
Proto-oncogenes and tumor suppressor genes play a critical role in regulation of 
proliferation and tumorigenesis. Activating mutations of proto-oncogenes 
promote transformation of normal cells into malignant ones. Furthermore, 
inactivated tumor suppressor genes, which normally inhibit cell division and 
promote cell death, cause loss of the negative control of the cell (Nielson et al., 
2004). 
1.6.1 Receptor Tyrosine Kinases 
The epidermal growth factor receptor (EGFR) family consisting of EGFR, ErbB2, 
ErbB3 and ErbB4 is responsible for growth regulation and differentiation in 
response to ligand binding and heterodimer formation among EGFR family 
members. The receptors are located in the cell membrane and show high 
structural homology. Neuregulins 1-4 serve as ligands for ErbB3 and ErbB4, 
while epiregulin and ß-cellulin activate ErbB1 and ErbB4. While ErbB2 is lacking 
a known ligand, ErbB3 lacks a functional kinase domain. Ligand binding induces 
ErbB (hetero-) dimer formation, whereas one ErbB kinase domain activates its 
dimer-partner. This leads to autophosphorylation or transphosphorylation of 
tyrosine residues that causes interaction between the activated receptor and 
SH2 or adapter proteins, which promote further downstream signaling (Citri et 
al., 2006). Several ovarian carcinomas show abnormal expression and abnormal 
signaling through EGFR pathways that confer negative prognosis in malignancy 
(Graeff et al., 2008). EGFR is reported to be overexpressed in more than 55% of 
ovarian cancers (Lassus et al., 2006) and more than 35% harbour molecular 
aberrations in ErbB2 (Lassus et al., 2004). However, several clinical studies 
document that monotherapies with EGFR or ErbB2 inhibitors or antibodies are 
largely inefficient against ovarian cancer (Reibenwein et al., 2008). 
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1.6.2 Phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR/p70S6K 
It is reported that a proportion of ovarian carcinomas harbor molecular 
aberrations of PI3K and/or PTEN. Receptor tyrosine kinases activate PI3K that is 
involved in many cellular functions such as proliferation, differentiation, 
tumorigenesis, angiogenesis and anti-apoptosis. Amplification of PI3K is 
observed in approximately 40% of ovarian carcinoma cell lines and patient tumor 
samples (Shayesteh et al., 1999;  Meng et al., 2006). PI3K can be activated by 
the ErbB receptor tyrosine kinase family or via insulin-like growth factor-I 
receptor, which can interact with ErbB receptors to integrate signals across 
distinct signaling pathways (Olayioye et al., 2000). The tumor suppressor gene 
Phosphatase and Tensin homolog (PTEN) is mutated especially in advanced 
ovarian carcinomas and decreased PTEN expression is associated with 
enhanced progression of the tumor. PTEN is a lipid phosphatase that 
counteracts PI3K by removing phosphate from the D3 position of the inositol ring 
of PIP3 (Datta et al., 1999). The best known downstream target of PI3K is the 
serine-threonine kinase AKT, which has three isoforms that share high structural 
homology. AKT is recruited to the plasma membrane and binds to PIP3 via the 
pleckstrin homology domain, becomes phosphorylated by PDK1 at Thr308 and 
finally by PDK2 at Ser473 (Stephens et al., 1998). AKT1 kinase activity is 
frequently enhanced in a proportion of ovarian carcinomas and several studies 
have established that AKT activation promotes tumor cell survival, cancer cell 
growth and invasiveness (Datta et al., 1999). Phosphorylation of AKT at Ser473 
can also be driven by mammalian target of rapamycin (mTOR) associated with 
rapamycin-insensitive companion of mTOR (rictor) which is also named 
mTORC2 (Sarbassov et al., 2006). AKT directly phosphorylates tuberous 
sclerosis complex 2 (TSC2, tuberin) on multiple sites that abrogates the 
inhibitory effects of the TSC1-TSC2 complex on Rheb and mTOR (Huang et al., 
2009). AKT can phosphorylate mTOR directly too (Manning et al., 2002). The 
mTOR signaling is also observed to be constitutively activated in several cancers 
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(Gao et al., 2004). The mTOR is phosphorylated by PI3K/AKT at Ser 2448. 
(Nave et al., 1999). In response to low energy levels or under hypoxic conditions 
the function of mTOR is blocked by tuberous sclerosis complex proteins TSC1 
and TSC2 (Easton et al., 2006). The mTOR is a serine-threonine kinase that by 
substrate phosphorylation transmits activation from AKT to p70S6K and 
inactivates eukaryotic initiation factor 4E (eIF4E) inhibitor binding protein 1 
(4eBP1) that normally blocks cap-dependent translation. Phosphorylation of 
4eBP1 at Ser65 by mTOR results in release of eIF4E and activation of cap-
dependent mRNA translation. The downstream effector protein p70S6K is a 
serine-threonine kinase. In total, two isoforms of S6K with 2 splice variants each 
have been identified: The cytoplasmatic p70S6K1 and p54S6K2 and the nuclear 
p85S6K1 and p60S6K2. Phosphorylation of p70S6K at Thr389 is closely related 
to its kinase activity (Pullen et al., 1997). The p70S6K1 is an important cascade 
molecule downstream of PI3K and AKT in tumor cell progression and 
proliferation (Meng et al., 2006;  Gao et al., 2004) and ubiquitination-dependent 
degradation of p70S6K1 has recently been associated to the regulation of its 
steady-state level (Wang et al., 2008). Moreover, S6K1 is reported to be 
overexpressed or constitutively active in early stages of transformation in ovarian 
epithelium with BRCA1 mutations (Easton et al., 2006). The p70S6K 
phosphorylates the S6 protein of the 40S ribosomal subunit and is involved in 
translation control.  
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Figure 1: Scheme of PI3K/AKT/mTOR/p70S6K signaling cascade 
Source: “Cell Signaling Technology Inc. , 2007-2008, Catalog and Technical Reference, 
p.125, mTOR” – with modifications 
1.6.3 Fatty Acid Synthase (FASN) 
It is documented that FASN protein is overexpressed in more than 80% of 
ovarian carcinomas (Alo et al., 2000). Furthermore, FASN has been identified as 
an independent prognostic factor for clinical outcome in ovarian cancer and 
increased expression of FASN in ovarian neoplasms predicts shorter survival 
(Graeff et al., 2008; Reibenwein et al., 2008; Gansler et al., 1997). Moreover, 
inhibition of FASN causes growth arrest in breast cancer and delays disease 
progression of ovarian carcinomas in xenograft models (Gansler et al., 1997;  
Pizer et al., 1996). Cancers usually reveal increased de novo lipogenesis as fatty 
acids are essential for all biological membranes and important for energy 
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metabolism. Normal cells usually prefer exogenously-derived fatty acids for the 
synthesis of new lipids. The biosynthesis of endogenously-synthesized fatty 
acids is catalyzed by the multifunctional, homodimeric enzyme fatty acid 
synthase (FASN) that is 250-270 kDa in size (Wakil et al., 2004). In normal 
conditions FASN converts excess carbohydrate into fatty acids that are then 
converted into triacylglycerols which can provide energy through ß-oxidation if 
needed. During ß-oxidation acyl-coenzymeA (CoA) is broken down to acetyl-CoA 
in the mitochondria of the cell. Acetyl-CoA is then the entry molecule for the citric 
acid cycle. The main product of FASN is a 16-carbon fatty acid, palmitate that is 
synthesized by using acetyl-CoA and malonyl-CoA as carbon donor and NADPH 
as reducing agent. Besides the exacerbated de novo biogenesis of fatty acids in 
cancer cells, high levels of carbon flux through aerobic glycolysis are hallmarks 
of tumors and provide them growth advantages. This rapid consume of glucose 
under aerobic conditions in tumor cells is named Warburg effect. In cancer cells 
there are many enzymes involved in metabolism of glucose to fatty acids (Figure 
2).  
1.6.3.1 Biosynthesis of endogenously-synthesized fatty acids 
First, glucose is taken up via glucose transporters and converted to glucose-6-
phosphate by hexokinase. Most of the glucose-6-phosphate is used for ATP 
generation by the glycolytic pathway. Therefore, pyruvate is converted to acetyl-
CoA that enters the mitochondrian citric acid circle to generate ATP. Requisite 
citrate, which could not be fully oxidized is converted back into acetyl-CoA by 
ATP citrate lyase (ACLY). The rate limiting enzyme acetyl-CoA carboxylase 
(ACACA) carboxylates a proportion of acetyl-CoA into malonyl-CoA. FASN 
condensates acetyl-CoA and malonyl-CoA to the 16 carbon saturated fatty acid 
palmitate and is dependent on NADPH, which is used as the reducing agent in 
this reaction. NADPH can be acquired through the pentose phosphate pathway. 
Palmitate and other saturated long-chain fatty acids can be converted into more 
complex fatty acids that are then used for synthesis of phospholipids, 
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triglycerides, cholesterol esters or acetylated proteins. Under anaerobic 
conditions pyruvate can also be used for the production of lactate by lactate 
dehydrogenase (LDH). In this case accumulated lactate is secreted out of the 
cell (Menendez et al., 2007) 
 
Figure 2: Warburg effect connected with fatty acid biosynthesis in cancer cells 
Source: “Menendez, Lupu, Nature Reviews Cancer, 7, 763 (2007)” 
1.6.3.2 Regulation of FASN expression in tumor cells 
One of two main pathways to regulate tumor associated FASN expression in 
cells is to phosphorylate receptor tyrosine kinases such as EGFR or ErbB2 via 
growth factor dependent phosphorylation or growth factor independent 
autophosphorylation that triggers a downstream activation of PI3K/AKT. Steroid 
hormones such as estradiol, progestin and androgen, which can bind to their 
corresponding steroid hormone receptors also lead to a downstream activation. 
In tumor cells FASN induction is constitutively driven because of hyperactivation 
of these pathways due to overproduction of growth factors, loss of PTEN function 
 Introduction 
 14 
and amplification of PI3K. However, in normal adipocytes and hepatocytes FASN 
expression is regulated by carbohydrates, fatty acids and fasting. The expression 
of FASN is directly modulated by the helix-loop-helix leucine zipper transcription 
factor sterol regulatory element-binding protein 1c (SREBP1c) that binds to the 
promoter region of FASN. Inactive SREBP1c precursor protein (pSREBP1c) is 
anchored in the membrane of the endoplasmatic reticulum (ER) and can be 
released by its activating protein SCAP. When enough activating signals have 
entered the cell, the SCAP-pSREBP1c complex moves from the ER membrane 
to the Golgi apparatus membrane where pSREBP1c is then cleaved by 
proteases releasing the cytoplasmatic domain, which translocates into the 
nucleus and transcribes FASN (Menendez et al., 2007) (Figure 3).  
The second pathway to achieve enhanced FASN expression in tumor cells takes 
place at a post-translational level. Normally, FASN protein level is modulated via 
ubiquitin-dependent proteasomal degradation. In prostate cancer cells, it has 
been observed that FASN interacts with the ubiquitin-specific protease named 
USP2 that removes ubiquitin from FASN and rescues FASN from proteasomal 
degradation (Graner et al., 2004) (Figure 3). 
1.6.3.3 Crosstalk between EGFR family members and FASN 
Phospholipids generated by FASN are integrated into membrane lipid rafts that 
localize membrane receptor tyrosine kinases such as the EGFR family members. 
Thus, formation of increased membrane lipid rafts by enhanced FASN activity 
initiates more signaling of receptor tyrosine kinases for proliferation and survival 
in tumor cells (Menendez et al., 3,  2005; Grunt et al., 2009) (Figure 3). Crosstalk 
between FASN and oncogenic PI3K/AKT pathway has been discussed in two 
recent puplications. Wang et al observed that in ovarian carcinoma cells AKT 
activation regulates FASN expression whereas FASN activity modulates AKT 
activation (Wang et al., 2005). Grunt et al also demonstrated that inhibition of 
FASN reduces EGFR and sensitizes ovarian carcinoma cells against ErbB 
targeting agents (Grunt 2009 BBRC). Moreover, several mechanisms are known 
 Introduction 
 15 
that regulate ErbB2 signaling by FASN. First, blocking of FASN leads to 
accumulation of its substrate malonyl-CoA, which enhances nuclear PEA3 that 
represses ErbB2 transcription (Menendez et al., 5, 2004). Second, FASN 
inhibition leads to an accumulation of NADPH. NADPH activates NADPH 
oxidase (NOX) that generates reactive oxygen species (ROS), which disables 
ErbB2 expression (Menendez et al., 2007) (Figure 3). Third, FASN blocking 
reduces synthesis of phospholipids integrated into the membrane lipid rafts. 
Therefore, ErbB2 receptors cannot be accommodated into the lipid raft 
aggregates and are recycled by endocytosis and lysosomal degradation (Nagy et 
al., 2002) (Figure 3). Fourth, activation of PI3K/AKT by FASN is reported to 
upregulate the transcription factor Sp1 (Jin et al.,  2007). The protein Sp1 
stimulates EGFR transcription via binding to the EGFR promoter which contains 
Sp1 motif (Liu et al., 1,  2005). Interestingly, FASN promoter also contains some 
Sp1 transcription factor binding sites (Roder et al., 1999). Thus, maybe FASN 
activates an autostimulatory loop by AKT that may increase both FASN and 
EGFR transcription (Figure 3). Fifth, a recent report indicates that hypoxia 
induces phosphorylation of AKT at Ser 473 which in turn activates SREBP1c to 
enhance FASN transcription (Furuta et al., 2008) 
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Figure 3: Crosstalk between EGFR family members and FASN 
Source: ”Grunt et al, BBRC, 2009” 
1.6.3.4 FASN Inhibitors 
As FASN expression is enhanced in more than 80% of ovarian carcinomas (Alo 
et al., 2000) it provides an attractive target for cancer therapy. That means that 
pharmacological FASN inhibitors selectively kill tumor cells and delay disease 
progression of ovarian carcinomas in xenograft models (Gansler et al., 1997; 
Pizer et al., 1996). The mammalian FASN is a multifunctional homodimeric 
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enzyme. Each of its two identical polypeptides includes seven catalytic domains: 
ß-ketoacyl synthase (KS) domain, malonyl/acetyltransferase (MAT) domain, 
dehydrase (DH) domain, enoyl reductase (ER) domain, ß-ketoacyl reductase 
(KR) domain, acyl carrier protein (ACP) domain and thioesterase (TE) domain 
(Wakil et al., 2004). Five well known drugs blocking FASN activity are as 
following: The FASN inhibitor cerulenin is a natural product isolated from 
Cephalosporium caerulens. It covalently binds to the KS domain of FASN 
thereby prohibiting the condensation between the fatty acid chain and acetyl or 
malonyl molecules. Cerulenin is chemically instable and possesses a reactive 
epoxy group which limits its clinical relevance (Lupu et al., 2006). Orlistat blocks 
the TE domain of FASN and thus prevents releasing of the end-product palmitate 
(Knowles et al., 2004). Furthermore, orlistat has a poor solubility, which excludes 
it as an anti-ovarian cancer drug (Menendez et al., 2, 2005). Triclosan inhibits 
the ER domain of FASN and accumulates unsaturated enoyl thioester 
intermediate (Liu et al., 2002). The well known green tea component 
epigallocatechin-3-gallate (EGCG) blocks the KS domain of FASN and naturally 
occurring polyphenols with similar chemical structures such as luteolin, quercetin 
or kaempferol also inhibit FASN activity by binding this domain (Brusselmans et 
al., 2005). In this report we used C75 for FASN inhibition in our experiments. 
C75 especially blocks the KS domain of FASN and resembles cerulenin without 
its reactive epoxy group that makes C75 chemically more stable. Structurally, 
C75 is a cell permeable α-methylene-γ-butyrolacetone which is less reactive 
than. In contrast to cerulenin, which only blocks the KS domain of FASN, C75 
also inhibits ER and TE domain of FASN. Furthermore, C75 is a competitive 
inhibitor of acetyl-CoA, malonyl-CoA and NADPH. Besides the cytotoxic effects 
in cancer cells, C75 is also proposed as an anti-obesity agent. As C75 blocks 
activity of FASN its substrate malonyl-CoA accumulates in the cells that normally 
has an inhibitory effect on carnitine palmitoyl transferase 1 (CPT1). This usually 
regulates mitochondrial fatty acid ß-oxidation. As C75 also acts as a malonyl-
CoA blocker, it can antagonize its effects on CPT1 and can drive ß-oxidation. A 
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second anti-obesity effect of C75 is the modulation of the metabolism in the 
hypothalamus, where it mediates appetite suppression via malonyl-CoA 
accumulation (Bentebibel et al., 2006). Patients suffering from cancer should not 
loose weight and adipose mass. Thus, novel designs of C75 have been 
synthesized, but explicit results concerning effects on CPT1 expression are still 
missing (Wang et al., 2009).  
 
Figure 4: Blocking sites of FASN inhibitors 
Source: “Menendez, Lupu, Nature Reviews Cancer, 7, 763 (2007)” 
1.6.3.5 Cytotoxic Effects of FASN Inhibition in Cancer Cells 
Inhibition of FASN causes growth arrest in breast cancer cells and delays 
disease progression of ovarian carcinomas in xenograft models (Gansler et al., 
1997; Pizer et al., 1996). There are several mechanisms that can explain the 
cytotoxic effects due to FASN inhibition. Blockade of FASN activity leads to 
 Introduction 
 19 
accumulation of its substrate, malonyl-CoA, which is an inhibitor of CPT1 
regulated ß-oxidation. Decreased ß-oxidation accretes ceramides that induce 
transcription of apoptotic genes such as DAP kinase, BNIP3 and TRAIL 
(Bandyopadhyay et al., 2006). FASN inhibition induces apoptosis in tumor cells 
lacking p53 rather than in cells with intact p53. Whereas blocking of FASN leads 
to growth arrest in cancer cells containing a functional p53 tumor suppressor 
gene, FASN inhibition leads to a genotoxic stress and apoptosis in p53 deficient 
cells (Menendez et al., 1, 2005). As FASN is responsible for synthesis of 
membrane phospholipids, an end product starvation in highly proliferating tumor 
cells induces apoptosis selectively in these cells (Rodriguez-Gonzalez et al., 
2005). Furthermore, FASN inhibition modulates lipid raft formation and 
decreases correct localization and function of tyrosine kinase receptors in the 
membranes (Nagy et al., 2002). Moreover, it has been observed that 
downregulation of FASN leads to decreased AKT activity and to decreased anti-
apoptotic signaling of this pathway (Wang  et al., 2005). It is well known that 
FASN inhibition leads to cell cycle arrest in G1 by several mechanisms. During 
G1 and S phase the phospholipid biosynthesis is normally greatest to prepare 
the cell for following division. The blocking of the cell cycle by FASN inhibition is 
reported to be caused by cyclin-dependent kinase inhibitors such as p21 or p27, 
BRCA1, SKP2 and nuclear factor κB (NF κB) (Knowles et al., 2004; 
Bandyopadhyay et al., 2006; Menendez et al., 4, 2004). Furthermore, it is 
documented that transcription of cyclin-dependent kinase inhibitor p15INK4b 
mRNA is upregulated after mTOR and p70S6K inhibition (Heinonen et al., 2007). 
As mTOR and p70S6K are downstream of AKT, which is decreased after FASN 
blocking, we hypothesize that p15 transcription could be upregulated that way. 
The enhanced mRNA transcription of cyclin-dependent kinase inhibitor p15INK4b 
could also be due to increased activity of forkhead box O (FOXO) transcription 
factors. FOXOs are negatively regulated by AKT phosphorylation (Katayama et 
al., 2008) which is decreased by FASN inhibition. Thus, FASN inhibition may 
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lead to decreased AKT activity that could induce FOXO-dependent p15INK4b 
transcription, which may finally enhance G1 cell cycle arrest.  
 
Figure 5: Several molecular mechanisms of the tumoricidal Effects of FASN Inhibition 
Source: “Menendez, Lupu, Nature Reviews Cancer, 7, 763 (2007)” 
1.6.4 Cell cycle control at G1/S checkpoint 
Enhanced unscheduled proliferation in tumor cells frequently is caused by 
hyperactivation of cell-cycle cyclin-dependent kinases (Cdks) through 
amplification, mutation or overexpression of cyclins and frequent inactivation of 
Cdk inhibitors (Malumbres et al.,  2001). In fact, alteration of Cdk inhibitors is a 
frequent event in several tumor types. The tumor suppressor proteins p15INK4b 
and p16INK4a are inhibitors of Cdks that prevent the cell from going through the 
G1-S phase transition.  
Inactivation of p15INK4b and p16INK4a genes, which are lokalized on the band p21 
of chromosome 9 has been detected in various human tumors and is thought to 
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be an important step in cancer development (Herman et al., 1996). Via 
polymerase chain reaction (PCR)-based analysis homozygous deletions of 
p16INK4a were detected in 7% ovarian carcinomas, while homozygous deletions 
of p15INK4b were detected in 33% ovarian carcinomas (Wong et al., 1997). 
Furthermore, it is well documented that more than 33% of ovarian carcinomas 
harbor p15INK4b methylation and more than 19% show p16INK4a methylation that is 
associated with transcriptional silencing of these tumor suppressor genes (Liu et 
al., 2, 2005; Rojas et al., 2009; Katsaros et al., 2004; Tam et al., 2007). The most 
common tumor suppressor gene p53 encodes a 53 kDa nuclear protein. 53% of 
patients suffering from ovarian cancer are reported to overexpress mutant p53 
protein (Nielsen et al., 2004). The tumor suppressor p53 induces G1 cell cycle 
arrest following DNA damage. Besides, it regulates transcription, differentiation, 
senescence, genomic instability, apoptosis and survival as well as glucose 
metabolism, oxidative stress and angiogenesis. Normally the protein level of p53 
is low due to its short half-life. Mutations in p53 lead to a more stable, but 
inactive protein that is resistant to degradation that results in accumulation of p53 
in the nucleus. Currently, p53 alterations are the most common defects, which 
are identified in epithelial ovarian cancers (Darcy et al., 2008) and are also 
associated with poor prognosis (Nielsen et al.,  2004). Ovarian cancers that 
show inhanced expression of p53 protein contain mutations in conserved regions 
of the p53 gene. These mutations are predominantly transitions, which suggests 
that they arise spontaneously rather than being caused by carcinogen exposure 
(Berchuck et al., 1994).  
The tumor suppressors p15INK4b and p16INK4a are homologous inhibitors of the 
cyclin-dependent kinases CDK4 and CDK6 and control the commitment of 
eukaryotic cells to transit the gap1 (G1) phase and enter the DNA synthesis (S) 
phase. The binding of p15INK4b or p16INK4a to CDK4 and CDK6 induces an 
allosteric change which abrogates the association of these kinases to D-type 
cyclins (cyclin D1) forcing a kinase inactive state. In contrast, the tumor 
suppressor p21 binds CDK2/CyclinE complexes forming ternary structures (Kim 
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et al., 2006). It has been shown that p21 plays a major role in inducing p53-
dependent G1 cell cycle arrest following DNA damage (Malumbres et al., 2003). 
Thus, phosphorylation of retinoblastoma (Rb) proteins is inhibited (Kim et al., 
2006). Phosphorylation of Rb by CDK4/6 or CDK2 dissociates the repressor Rb 
from E2F transcription factor permitting transcription of S-phase promoting 
genes. Accordingly, p15INK4b, p16INK4a or p21CIP1 maintains Rb in a 
hypophosphorylated state that promotes binding to E2F, which prevents G1 – S 
phase transition (Harbour et al., 2000).  
 
Figure 6: Mechanism of cyclin dependent kinase inhibitors 
Source: ”Cancer Control, 2004, Lee Motfitt ,Cancer Center and Research Institute, Inc.” 
(http://www.medscape.com) – with modifications. 
1.6.5 Epigenetic gene silencing in cancer 
DNA methylation is a naturally occurring event in organisms in order to protect 
host DNA from digestion by restriction endonucleases, which are designed to 
eliminate foreign DNA. In higher eukaryotes DNA methylation is implicated in 
gene expression control during genetic imprinting, embryonic development, X-
chromosomal silencing and cell cycle regulation (Costello et al., 2001). 
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Furthermore, it is well known that DNA hypermethylation is involved in cancer 
development (Stirzaker et al., 1997). During DNA methylation a methyl group is 
added to the fifth carbon position of the cytosine pyrimidine ring by DNA 
methyltransferase enzymes (DNMTs). Most DNA methylation modifications occur 
in 5´-CpG-3´dinucleotides. About 80 percent of all 5´-CpG-3´dinucleotides in 
human genomes are methylated. The remaining twenty percent unmethylated 
are located within promoter regions or in the first exons of genes (Adams et al., 
1995). Many tumor suppressor genes are reported to be promoter 
hypermethylated. Aberrant methylation of CpG islands in promoter regions of 
p15INK4b (Herman et al., 1996) and p16INK4a (Katsaros et al., 2004) as well as 
gene methylation of DAP Kinase (Collins et al., 2006) and CDH1 (Rathi et al., 
2002; Makerla et al., 2005) has been observed. Several types of tumors, 
including ovarian cancer, are known to have a hypermethylation phenotype 
(Esteller et al., 2001; Strathdee et al.,  2001). It is shown that in a proportion of 
ovarian carcinomas aberrant promoter methylation of CDH1 gene (≤42%) is 
detected and that methylation status of CDH1 is closely associated with the 
decrease of E-Cadherin protein expression (Yuecheng et al., 2006). Especially, 
DAP kinase methylation is observed in 67% of patients with malignant ovarian 
carcinomas (Collins et al., 2006). Moreover, it is well documented that more than 
33% of ovarian carcinomas harbor p15INK4b methylation and more than 19% 
show p16INK4a methylation.  
As DNMT1 is reported to preference hemi-methylated substrates to maintain the 
methylation patterns following DNA replication, it accounts for basic methylation 
(Esteller et al., 2007). For example, DNMT1 methylates and silences multiple 
genes on the inactivated X chromosome of females (Collins et al., 2006). 
DNMT3a and DNMT3b are known to be responsible for de novo methylation. 
However, novel studies indicate that DNMT1, DNMT3a and DNMT3b posses all 
de novo and maintenance functions (Esteller et al., 2007). The conserved amino-
terminal domains of the four core histones (H2A, H2B, H3 and H4) contain 
lysines that are acetylated by histone acetyltransferases (HATs) and 
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deacetylated by histone deacatylases (HDACs). Removal of acetyl groups from 
histone lysine tails by HDAC increases the ionic interactions between the 
positively charged histones and the negatively charged DNA resulting in a 
compact transcriptionally repressive chromatin state. Histone hypoacetylation is 
not always explained by HDAC hyperactivation but also can be due to decreased 
HAT activity caused by mutations or chromosomal translocations (Espada et al., 
2004). Methyl-CpG binding proteins (MBDs) are associated to methylated DNA 
and HDAC-containing complexes to establish a transcriptionally inactive 
chromatin environment. Thus, hypermethylated CpG islands of silenced tumor-
suppressor genes are characterized overall by histone methylation and histone 
hypoacetylation (Esteller et al., 2007).  
1.7 The Ubiquitin/Proteasome pathway 
The ubiquitin/proteasome pathway leads to specific degradation of several 
proteins with a low half-life period and is conserved from yeast to mammals in all 
eukaryotic cells. Proteins, which have not been properly fold, or cell cycle 
proteins, which have to be eliminated for purposes of regulation, but also for 
quantity control are targeted to be reduced by proteasomal degradation. 
Ubiquitin modification of proteins is ATP-dependent and occurs through 
sequential steps catalyzed by three classes of enzymes. The ubiquitin activating 
enzyme (E1) forms a thio-ester bond with ubiquitin. Therefore, the ubiquitin 
conjugating enzyme (E2) can join ubiquitin, a 76 amino acid polypeptide, at its 
carboxy-terminus to the lysine of target proteins through an isopeptide bond. 
Then, several ubiquitin ligase enzymes (E3) pass the ubiquitin to the substrate 
and provide specificity in modifying target proteins. To target a protein for 
proteasomal degradation multiple ubiquitination cycles are needed that result in 
a polyubiquitination chain. Monoubiquitination acts as a signal for intracellular 
trafficking, while polyubiquitination of proteins results in recruitment of the 26S 
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proteasome and degradation. The 26S proteasome is a 2,5MDa complex, 
multisubunit protein that recognizes, unfolds and degrades targeted proteins. 
The proteasome uses energy from ATP hydrolyses to unfold the targeted 
proteins and to translocate the polypeptide chain into the cylindrical core of the 
complex (Pickart et al., 2004). The specificity of proteasomal degradation is 
achieved by several types of E3, each of which can only modify a subset of 
proteins. Moreover, specificity is provided by post-translational modifications of 
the target proteins including phosphorylation. However, up to date a conclusive 
molecular mechanism for specific targeting of proteins for ubiquitin-dependent 
proteasomal degradation remains elusive. As ubiquitin-dependent degradation is 
often involved in cell cycle control and cell growth, proteasome inhibitors are 
currently under investigation as anti cancer drugs (Adams et al., 2004). 
 
Figure 7: The Ubiquitin/Proteasome pathway 
Source: “Cell Signaling Technology Inc., 2007-2008, Catalog and Technical Reference, 
p.402” 
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This work is the first report about the epigenetically modulating activity of FASN 
inhibition. We further pointed out several effects of FASN blocking including 
enhanced ubiquitin-dependent protein degradation and downregulation of PI3K 
signaling. Moreover, we could confirm anti-proliferative and apoptosis-inducing 
actions induced by FASN inhibition. 
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2 Materials and Methods 
2.1 Cell culture and Cell line 
In our experiments we used the human ovarian carcinoma cell line A2780, which 
was isolated from an untreated patient. The A2780 cell line was obtained from M. 
Krainer, Medical University of Vienna, in early passages. This epithelial cell line 
grows adherently and forms a monolayer. It is cultivated in RPMI1640 medium 
(Gibco, 32404-014) supplemented with 10% heat inactivated fetal calf serum 
(FCS) (Gibco, 10270-106), 100 U/ml Penicilline and 100mg/ml Streptomycine 
(PenStrep) (Gibco, 15140-148) and 2mM L-Glutamine (Gibco, 25030-032). After 
preparation of the culture medium, the medium always was sterile filtered by 
sterile bottle filter system with 0,2µm diameter. Moreover, all preparations with 
living cells were performed under sterile conditions in laminar air flow hood 
(HERAsafe). 
2.1.1 Maintenance of Cells  
The cell line A2780 was maintained at 37°C in a 5% carbon dioxide atmosphere 
with 95% relative humidity. The cell line was cultivated on 25cm2 tissue culture 
flasks (Falcon, 353009) in 7ml of the medium containing 10% FCS, 100U/ml 
Penicilline, 100µg/ml Streptomycine and 2mM L-Glutamine. At a confluence of 
approximately 90%, cells were passaged. After removal of the culture medium 
the cells were washed with PBS Dulbecco´s (Gibco, 14190-094) and incubated 
with Trypsin/EDTA (Gibco, 25300-054) for 5 minutes at 37°C to detach them. 
Then the cells were resuspended in the RPMI1640 culture medium to obtain a 
single cell suspension and passaged at ratios from 1:15 to 1:20 corresponding to 
a density of about 1x106 cells in 7ml fresh culture medium. The fast growing 
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A2780 cells were passaged twice a week. Confluence, morphology and 
treatment effects were checked under light microscope. 
2.1.2 Storage of Cells 
To avoid long-term-effects, such as mutations, we used the cells for experiments 
only until passage 30. Therefore, we expanded the A2780 cells at a low passage 
and stored them at a density of 2x106 cells/ml in liquid nitrogen. For freezing, the 
cells were washed with PBS Dulbecco´s and incubated with Trypsin/EDTA for 5 
minutes at 37°C to detach them. Then the cells were resuspended in 5ml 
RPMI1640 culture medium, centrifuged at 1000rpm for 5minutes and again 
resuspended in only 3 ml culture medium to obtain a concentrated single cell 
suspension for counting. To select the intact cells, 20µl single cell suspension 
was incubated with 180µl 0,4% Trypanblue Solution (Sigma, T8154), whereas 
only the trypanblue solution excluding cells were counted in a counting chamber 
under the light microscope. The remaining 3ml cell suspension is then adjusted 
to 4x106 cells/ml in culture medium before it is diluted 1:2 with culture medium 
supplemented with 20% dimethyl-sulfoxide (DMSO)(Sigma, D2650) to a final 
DMSO concentration of 10% and 2x106 cells/ml. Before 1ml of the adjusted cell 
suspension was transferred into liquid nitrogen, the cells were slowly frozen in 
cryotubes (NUNC, 368632) in an isolating Styrofoam box at -80°C for 48 hours. 
In the end, the cells were stored in liquid nitrogen for years. For experiments, we 
quickly thawed the cells. For this purpose, we transferred the cryotube from 
liquid nitrogen directly into a beaker filled with ice before the vial was then 
thawed in a beaker containing warm water. Afterwards, the 1ml cell suspension 
was transferred into a 50ml falcon tube containing precooled 10ml culture 
medium and centrifuged at 1000rpm for 5minutes at 4°C. The cell pellet 
containing 2x106 cells was resuspended with 1ml culture medium and sowed into 
a tissue culture flask. The cells were at least cultured 2 weeks to recover before 
they were used for experiments.  
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2.1.3 Used drugs 
Cells were treated for the indicated times and drug concentrations.  
The FASN inhibitor C75 (Sigma, C5490) was dissolved in DMSO under sterile 
conditions and stored at -80°C. Further dilutions were made in culture medium. 
C75 is a small molecule inhibitor of the ketoacyl synthase domain (KS) of FASN, 
thus preventing the condensation reaction between the elongating fatty acid 
chain and successive acetyl or malonyl residues. C75 is a cerulenin-derived 
semi-synthetic FASN inhibitor lacking the reactive epoxy group of cerulenin. In 
contrast to cerulenin, C75 additionally inhibits enoyl reductase and thioesterase. 
Moreover, C75 is a competitive irreversible inhibitor of acetyl-CoA, malonyl-CoA, 
and NADPH (Price et al., 2001; Reninda et al., 2005). In mice, C75 treatment 
induces rapid and profound weight loss and loss of adipose mass by affecting 
food intake and energy expenditure. These side effects of C75 preclude its 
development as an anti-tumor agent. Nevertheless, C75 has been used as a 
leading compound for discovering the role of FASN in obesity and cancer (Wang 
et al., 2009; Menendez et al., 2007). Optimal effects of FASN inhibition were 
obtained with 7µg/ml concentration of C75 in A2780 cells (Grunt et al.,  2009). 
 
 
Figure 8: Chemical Structure of C75 
 
The PI3K inhibitor LY294002 (Calbiochem, 440202) was dissolved in DMSO 
under sterile conditions and stored at -80°C. Further dilutions were made in 
culture medium. LY294002 is a cell-permeable, potent, and specific 
phosphatidylinositol 3-kinase inhibitor that acts on the ATP-binding site of the 
enzyme. We used this inhibitor at a concentration of 40µM in A2780 cells. 
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Figure 9: Chemical structure of LY294002 
 
The translation inhibitor Cycloheximide (CHX) (Sigma, C1988-1G) was 
dissolved in DMSO under sterile conditions and stored at -80°C. Further dilutions 
were made in culture medium. Cycloheximide is an elongation inhibitor. It blocks 
the translation of messenger RNA on cytosolic, 80S ribosomes, but does not 
inhibit organelle protein synthesis (Obrig et al., 1971). The optimal translation 
inhibition of the analyzed proteins was obtained at a final concentration of 15µ/ml 
in A2780 cells. 
 
 
Figure 10: Chemical Structure of Cycloheximide 
2.2 Gene expression analysis on mRNA level 
2.2.1 Treatment of Cells 
We plated 5,36x105 A2780 cells per tissue culture flask T25 (25cm2 growth area) 
or 16,08x105 cells per tissue culture flask T75 (75cm2 growth area). Cells were 
cultured in RPMI1640 supplemented with 5% FCS, 100U/ml Penicilline, 
100µg/ml Streptomycine and 2mM L-Glutamine. We let them adhere over night 
before we started the treatment with 7µg/ml of C75 or 40µM LY294002 or the 
DMSO solvent control (0,0389% for C75 and 0,1% for LY294002). We exposed 
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the cells to the agents for indicated times at 37°C protected from light. Exactly 
20minutes before homogenization we stimulated the cells with 100ng/ml 
epidermal growth factor (EGF) (Sigma, E9644). Then we checked the cell 
monolayer under the light microscope and noted confluence, morphology and 
apoptosis of the cells.  
2.2.2 RNA Isolation 
Homogenization 
For following procedures we used autoclaved material and wore sterile gloves in 
order to avoid degradation of RNA by RNAses which are very stable. 
Furthermore, we worked in laminar air flow hood because of the toxicity of some 
used reagents. We poured off the media and carefully removed any residual 
amounts of media with a blue Gilson pipet tip. Afterwards, 3ml cold TRI Reagent 
(Molec. Res. Ctr., TR118) per T25 or T75 were added to the cells. The culture 
flask was stored horizontally for at least 5min at room temperature before the cell 
lysate was passed through a pipette for several times. The homogenate was 
then distributed into two 2ml Eppendorf tubes (Eppendorf, 0030.120.094).  
 
RNA-Extraction 
For RNA extraction of the homogenised cells cold 0.15ml BCP (1-bromo-3-
chloropropane) (Molec. Res. Ctr., BP151) per sample containing 1.5ml TRI 
Reagent was added. Then each sample was vortexed for 15seconds and stored 
for 15min at room temperature before the probes were centrifuged at 12.500rpm 
for 15min at 4°C.  
 
RNA-Precipitation 
After centrifugation the sample was separated into two phases. The lower red 
organic phase and the white interphase contained DNA and proteins, whereas 
the upper colourless aqueous phase contained RNA. We carefully removed the 
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upper phase with a blue pipette tip avoiding the white interphase and transferred 
this volume to new 1,5ml Eppendorf tubes (0030120.086). 2ml Eppendorf tubes 
containing the interphase and lower phase were stored at -80°C for subsequent 
isolation of DNA for bisulfite conversion and following methylation specific PCR. 
For precipitation of RNA 1ml isopropanol (Sigma) was added to each sample, 
vortexed for 15seconds and stored on ice for further 30minutes. Then the probes 
were centrifuged at 12500rpm for 15minutes at 4°C to pellet the precipitated 
RNA of cells. 
 
RNA-Wash 
To gain pure RNA we carefully aspirated the supernatant with a self-drawn 
Pasteur pipette connected to a water-jet vacuum pump and added 1.5ml 75% 
EtOH per sample (Merck). After vortexing the pellet became visible and 
depending on the size of the pellet we could later adjust solubilization volume. 
 
RNA-Solubilization 
We carefully aspirated the EtOH supernatant with a self-drawn Pasteur pipette 
connected to a water-jet vacuum pump and air-dried the RNA pellets at room 
temperature until the white pellets became translucent. According to the pellet 
size RNA was dissolved in sterile Aqua bidest by passing the solution several 
times through a yellow pipette tip. As we obtained 2 Eppendorf tubes per 
experimental sample we pooled the adequate samples and stored them on ice 
for further analysis or for long term storage at -80°C. 
2.2.3 RNA-Measurement 
Qualitative RNA control 
We checked the quality of the isolated RNA by 1% agarose-gel electrophoresis 
(‘check gel’). Therefore, we used a small electrophoresis unit with 15-slot comb 
and prepared 250ml running buffer containing 1xTAE (Sigma, T9650). For 1% 
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agarose gel we added 0,3g Saekem Agarose (Sigma) to 30ml 1xTAE, boiled the 
solution in a microwave until it became translucent, added 3µl 10 000 x GelRed 
nucleic acid gel staining solution (Biotium, BIB 41003) and poured the agarose 
gel containing 1xGelRed into the electrophoresis chamber. We then removed 
comb and restraining bars from the chamber after gel had polymerized after 
30minutes. 250ml of previously prepared 1xTAE running buffer was spilled into 
the electrophoresis chamber unit. Before RNA samples were loaded into the 
slots, each 0,5µl RNA sample was supplemented with 12µl Aqua Bidest and 3µl 
of 5xgel loading buffer (Sigma, G2526). 
The gel ran at constantly 70V for 40min. The isolated RNA could be detected by 
intercalated GelRed which was seen as bands at a different size. The gel was 
photographed with the Herolab Easy Gel Documentation System using adequate 
settings. When RNA quality was high there could be seen two predominant 
bands of small 18S rRNA (~2kb) and large 28S rRNA (~5kb). Sometimes 
additionally bulk mRNA (1 – 2kb), smear mRNA (2 – 7kb) and discrete bands of 
high molecular weight RNA (7-15kb) could be seen (Figure 11). When RNA was 
degraded during isolation a smear band containing spliced RNAs of all sizes 
could be observed instead of two predominand bands. 
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Figure 11: Example for Qualitative Control of Isolated Total RNA by 1% Agarose Gel 
 
Quantitative RNA measurement 
For adjusting RNA to a concentration of 0,2µg/µl for further cDNA conversion, we 
measured RNA quantity by a spectrophotometer (Eppendorf). Therefore RNA 
samples were placed on ice, mixed softly and diluted 1:250 in Aqua Bidest in 
adequate cuvettes. The optical densities of the probes were measured against 
that of Aqua Bidest at 260nm and 280nm wavelength. The quantity of RNA was 
calculated via multiplication of OD260 value by 40, which gave the amount of 
RNA in µg/µl. Furthermore we calculated the absorption ratio between 
OD260/OD280, which predicates the purity of the RNA from extraction reagents 
and should be between 1,7 and 2,2. If the ratio was less than 1,7, there was 
protein contamination in the sample, if the ratio was greater than 2,2, RNA 
degradation had occurred. Finally, the probes were adjusted to 0,2µg/µl RNA per 
sample with Aqua Bidest.  
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2.2.4 cDNA Synthesis 
For Real Time PCR we used cDNA as a template because Taq Polymerase in 
PCR was DNA dependent. Therefore, we converted an aliquot of isolated mRNA 
into cDNA by reverse transcription using random hexamer primers. For reverse 
transcription of mRNA following mix was prepared in an Eppendorf tube 
(amounts per sample): 
 
5xBuffer containing 50mM TrisHCL, 75mM KCl, 3mM Mg2Cl2 pH8,3 
supplemented with Reverse Transcriptase (Invitrogen, 28025-013) 
4µl 
DTT supplemented with Reverse Transcriptase (Invitrogen, 28025-013) 2µl 
nuclease free Bovine Serum Albumin (VWR, 11940.01) dissolved in 
DEPC water (VWR, 39798.03) to a final concentration of 2,9mg/ml 
1µl 
Protector RNAse inhibitor 40U/µl (Roche, 03335399001) 0,315µl
dNTP Set 25µM each (Amersham, 27-2035-01) 0,8µl 
Random Hexamer Primers 100µM (Amersham, 27-2166-01) 1µl 
MLV Reverse Transcriptase 200U/µl (Invitrogen, 28025-013) 1µl 
Aqua Bidest 0,185µl
Table 1: Mastermix for cDNA sythesis 
 
10µl (2µg) of adjusted RNA was added to Eppendorf tube containing 10,3µl of 
Mastermix, well mixed and incubated on a thermoblock at 37°C for 60minutes. 
Finally, the produced cDNA solution was stored at -80°C. 
2.2.5 Real Time RT-Polymerase Chain Reaction (PCR) 
Standard PCR is used to amplify a specific region of DNA, in order to produce 
enough DNA for detection. In general, every PCR is composed of the following 3 
steps:  
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1. Denaturation: the DNA double strands are melted through heat (95°C).  
2. Annealing: primers attach to the complementary sequences of the DNA 
template.  
3. Synthesis and Elongation: primers are extended by DNA polymerase and 
the complimentary strand is synthesized starting at the 3´end of the 
annealed primers. 
 
Standard PCR only gives qualitative information about a certain gene. That was 
the reason why we used quantitative Real Time RT-PCR for gene expression 
analysis.  
 
Real Time RT-PCR using Gene Specific Probes and Primers 
All PCRs were set up in laminar air flow hood whereas the UV-light in laminar air 
flow hood was turned on 20min before starting to avoid contamination. 
Furthermore, gloves, racks and Aqua Bidest were also exposed to UV-light 
before use. We performed Real Time RT-PCR using reagents of Applied 
Biosystems (ABI). 
In this system Real Time RT-PCR is based on the concept of 5´nuclease activity 
of the DNA Polymerase (AmpliTaq DNA Polymerase), which cleaves the probe 
containing covalently linked reporter dye at its 5´end and a quencher dye at the 
3´end oligonucleotide. The basic steps are presented in Figure 12:  
 
1. When the probe is intact, the proximity of the reporter to the quencher 
results in suppression of the reporter fluorescence, primarily by Förster 
energy transfer.  
2. After denaturation primers and probe hybridize to the complementary 
sequence of single stranded cDNA only if the gene if interest is present.  
3. The probe which consists of an oligonucleotide with a 5´ reporter dye and 
a 3´quencher dye specifically targets the region between the forward and 
the reverse primer.  
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4. The 5´ to 3´ nuclease activity of the DNA polymerase cleaves the probe 
between reporter and quencher dye. 
5. Cleavage of the probe separates the reporter dye from the quencher dye 
which results in increased fluorescence of the reporter. Probe fragments 
are displaced from the target and polymerization of the strand continues. 
Accumulation of PCR products is detected directly by monitoring the 
increase in fluorescence of the reporter dye.  
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Figure 12: Schemata of Real Time RT-PCR using Gene Expression Assay.  
Source: “da Silva A, Pieniazek N, Latest Advances and Trends in PCR-based Diagnostic 
Methods, Dionisio D (editor), Textbook-Atlas of Intestinal Infections in AIDS. Springer; 
2003. p. 397-412“ 
 
In our experiments we used TaqMan Universal PCR Mastermix (ABI, 4324018) 
containing DNA polymerase, dNTPs with dUTP and optimized buffer 
components with gene specific primers and probes from Applied Biosystems 
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(TaqMan gene expression assay). The gene specific sequences of primers and 
probes are under corporate secret but several appropriately designed primers 
and probes were available. The supplemented thermal stable Taq DNA 
Polymerase has 5´ to 3´ nuclease activity but it lacks 3´ to 5´ exonuclease 
activity. We used following TaqMan gene expression assays: 
 
p15INK4b , CDKN2b (ABI, TaqMan Gene Expression Assay) hs_00793225_m1
p16INK4a CDKN2a (ABI, TaqMan Gene Expression Assay) hs_99999189_m1 
HDAC2 (ABI, TaqMan Gene Expression Assay) hs_00231032_m1 
DNMT1 (ABI, TaqMan Gene Expression Assay) hs_00945899_m1 
DNMT3a (ABI, TaqMan Gene Expression Assay) hs_00602456_m1 
DNMT3b (ABI, TaqMan Gene Expression Assay) hs_00171876_m1 
DAP kinase (ABI, TaqMan Gene Expression Assay) hs_00234489_m1 
E-Cadherin, CDH1 (ABI, TaqMan Gene Expression Assay)hs_01013959_m1 
Aktin beta (ABI, TaqMan Gene Expression Assay) ACT 4352935E 
GAPDH (ABI, TaqMan Gene Expression Assay) 00266705_g1 
Table 2: TaqMan Gene Expression Assay Probes used for Real Time RT-PCR 
 
All used TaqMan gene expression assay probes were FAM or VIC (Actin beta) 
labeled. According to the manufacture´s protocol we prepared the Real Time RT-
PCR Mix as following (amounts per sample): 
 
TaqMan Universal PCR Mastermix 2x (ABI, 4324018) 12,5µl 
TaqMan Gene Expression Assay 20x (ABI, according to 
gene) 
1,25µl 
Aqua Bidest 10,25µl 
Table 3: PCR Mix for Real Time RT-PCR Containing TaqMan Gene Expression Assay 
Probes 
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Finally, 1µl (~100ng) of cDNA was added to 24µl of PCR mix into a 96 well 
optical reaction plate (ABI, 30103781) and spinned down in a centrifuge before it 
was put into a thermocycler with sequence detection system (ABI 7000). We 
prepared triplicates for every sample and solvent controls. Every run was set 
with probes for the genes of interest, negative controls containing no cDNA, and 
at least one house keeping gene. Thermal cycling conditions for all used primers 
and probes were as following: 
 
Activation of DNA Polymerase 95°C 10min Hold 
Denaturation 95°C 15min
40 CyclesAnnealing/Extension 60°C 1min 
Table 4: Cycling Conditions for Real Time RT-PCR using predeveloped TaqMan Gene 
Expression Assay Probes 
 
Analysis and Calculation of Gene Expression 
Analyzing the data from TaqMan Gene expression assays firstly requires to view 
the amplification plot and to set the baseline and threshold values according to 
the manufacture´s protocol. The threshold value was set in an area in which a 
significant increase of signal was first detected. The CT number represent the 
number of cycles which had to be run until the first adequate fluorescent signal 
could be detected for this probe. Therefore, the higher the CT number of a 
sample was, the lower was its gene expression level. GAPDH (p15, p16, 
HDAC2, DNMT1, DNMT3a, DNMT3b, CDH1, FAS, SOD2 and DAP kinase of 
C75-treated cells and p15, p16, HDAC2, DNMT1, DNMT3a, DNMT3b, FAS, 
SOD2, DAP kinase of LY294002-treated cells) or beta actin (CDH1 of 
LY294002-treated cells) was used as endogenous control. Gene expression was 
calculated by relating the CT values of control samples, which have been set at 
1, to those of C75 or LY294002 treated cells. Means of triplicate determinations, 
mean standard deviations and Student´s TTESTs were calculated in Excel.  
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2.3 Methylation Specific Real Time RT-PCR 
The most common technique to detect methylated DNA is to convert 
unmethylated cytosines into uracils whereas methylated cytosines remain 
unchanged during sodium bisulfite conversion. Therefore, sodium bisulfite is 
used to convert unmethylated cytosines to uracils, which are recognized as 
thymine by Taq polymerase, while 5´-methylcytosines remain unaltered. The 
converted DNA is then amplified by appropriate primers for methylated and 
unmethylated converted DNA sequences. So the individual steps in methylation 
specific PCR are as following: 
 
1. DNA isolation of cells 
2. Sodium bisulfite conversion of DNA 
3. PCR using primers for methylated DNA or unmethylated, converted DNA  
4. Detection of PCR products 
 
In our experiments we performed a quantitative Real Time PCR for detection of 
the bisulfite-converted DNA using SYBR Green dye molecules which intercalate 
into double stranded DNA. 
2.3.1 Treatment of Cells 
We plated 5,36x105 A2780 cells per tissue culture flask T25 (25cm2 growth area) 
or 16,08x105 cells per tissue culture flask T75 (75cm2 growth area). Cells were 
cultured in RPMI1640 supplemented with 5% FCS, 100U/ml Penicilline, 
100µg/ml Streptomycine and 2mM L-Glutamine. We let them adhere over night 
before we started the treatment with 7µg/ml of C75 or 40µM LY294002 or the 
DMSO solvent control (0,0389% for C75 and 0,1% for LY294002). We exposed 
the cells to the agents for indicated times at 37°C protected from light. Exactly 
20minutes before homogenization we stimulated the cells with 100ng/ml 
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epidermal growth factor (EGF) (Sigma, E9644). Then we checked the cell 
monolayer under the light microscope and noted confluence, morphology and 
apoptosis of the cells.  
2.3.2 DNA Isolation 
Homogenization 
For following procedures we used autoclaved material and wore sterile gloves in 
order to avoid degradation of DNA by DNAses which are very stable. 
Furthermore, we worked in laminar air flow hood because of the toxicity of some 
used reagents. We poured off the media and carefully removed any residual 
amounts of media with a blue Gilson pipet tip. Afterwards, 3ml cold TRI Reagent 
(Molec. Res. Ctr., TR118) per T25 or T75 were added to the cells. The flask was 
stored horizontally for at least 5min at room temperature before the cell lysate 
was passed through a pipette for several times. The homogenate was then 
distributed into two 2ml Eppendorf tubes (Eppendorf, 0030.120.094).  
 
DNA-Extraction 
For DNA extraction of the homogenised cells cold 0.15ml BCP (1-bromo-3-
chloropropane) (Molec. Res. Ctr., BP151) per sample containing 1.5ml TRI 
Reagent was added. Then each sample was vortexed for 15seconds and stored 
for 15min at room temperature before the probes were spun down at 12.500rpm 
for 15min at 4°C.  
 
DNA-Precipitation 
After centrifugation the sample was separated into two phases. The lower red 
organic phase and the white interphase contained DNA and proteins, whereas 
the upper colourless aqueous phase contained RNA. We carefully removed the 
upper phase containing RNA with a blue pipette tip avoiding the white 
interphase, transferred this volume to new 1,5ml Eppendorf tubes (0030120.086) 
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and stored them at -80°C for subsequent cDNA sythesis. Any residual aqueous 
phase was carefully removed which is important for the quality of the isolated 
DNA. Then 450µl pure ethanol was added to each 2ml Eppendorf tube 
containing DNA in the interphase and lower phase. Tubes were mixed via 
inversion and stored for 3 minutes at room temperature. Afterwards, the samples 
were centrifuged at 2000rpm for 5min at 4°C. 
 
DNA Wash 
The phenol-ethanol supernatant was carefully aspirated with a self-drawn 
Pasteur pipette connected to a water-jet vacuum pump. For the first wash, 1,5ml 
of 0,1M Soduim Citrate (Natriumcitrat tribasisch Dihydrat, Sigma-Aldrich, S4641-
25G) in 10% ethanol was added to the DNA pellet of each sample and inverted 
for several times during storage for 30 minutes at room temperature. After the 
first wash the samples were spun down at 2000rpm for 5 minutes at room 
temperature. Then the supernatant was carefully aspirated with a self-drawn 
Pasteur pipette connected to a water-jet vacuum pump. For the second wash, 
again 1,5ml of 0.1M Sodium Citrate in 10% ethanol was added per sample, the 
tubes were stored for 30 minutes at room temperature, mixed periodically, 
centrifuged, and finally the supernatant was aspirated. Very large pellets 
(>200ug) were washed a third time with 0,1M Sodium Citrate in 10% ethanol. 
After washing the DNA pellet with Sodium Citrate, the pellet was washed with 
2ml of 75% ethanol and stored at room temperature for 10 minutes. During this 
time the tubes were mixed and inverted for several times. Afterwards, the tubes 
were spun down at 2000rpm for 5 minutes at room temperature and the DNA 
pellets became visibly white.  
 
DNA Solubilization 
For DNA solubilization, we first aspirated the ethanol supernatant with a self-
drawn Pasteur pipette connected to a water-jet vacuum pump and air dried the 
DNA pellet for 3 minutes at room temperature. Then, the DNA pellet was 
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dissolved in ~20µl TE buffer solution (810mM TrisHCl; 1mM Disodium EDTA; 
pH8; Sigma, 93283-100ML) by slowly passing the solution through a pipette tip. 
The high molecular weight DNA increases the viscosity of the DNA solution and 
made it difficult to pool the two corresponding samples to a final volume of ~40µl. 
 
DNA-Measurement 
The quantity of DNA was measured by spectrophotometry (wave length 
260/280nm) on an Eppendorf photometer. The DNA samples were diluted and 
mixed 1:500 in Aqua Bidest and the photometer automatically calculated 
concentration and purity (260/280 ratio) of the DNA samples related to the Aqua 
bidest. Finally, the DNA samples were diluted in TE buffer up to a concentration 
of 20ng/µl and could be stored at -80°C. 
2.3.3 Sodium Bisulfide Conversion 
The most common technique to detect methylated DNA is to convert 
unmethylated cytosines into uracils whereas methylated cytosines remain 
unchanged during sodium bisulfite conversion. In our experiments we used the 
EZ DNA Methylation-Direct Kit (Zymo Research, D5020) in which DNA 
denaturation and bisulfite conversion processes were combined into a single 
step and desulfonation reaction and DNA clean-up was included. For every 
experiment we included a universal unmethylated human genomic DNA 
(Chemicon, S7822) as negative control and performed bisulfite conversion 
following the manufacture´s instructions: 
 
Sodium Bisulfite Conversion 
At the beginning, the light sensitive conversion reagent solution was freshly 
prepared by adding 790µl solubilization buffer and 300µl dilution buffer to the 
conversion reagent. This freshly prepared conversion reagent solution was 
mixed for 10 minutes before 160µl of reaction buffer was added and mixed for 
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one additional minute. Then, 400ng of sample or control DNA was added to 
130µl of conversion reagent solution to a final volume of 150µl into an Eppendorf 
0,2ml PCR-tube that was mixed and spin down. The PCR tubes (Applied 
Biosystems, N801-0540) were placed into the thermal iCycler (Biorad) to be 
converted at following temperatures: 
 
98°C 8min 
64°C 210min 
4°C hold 
Table 5: Conditions for Sodium Bisulfite Conversion 
 
After conversion of the DNA samples, the samples were load into a column in 
which 600µl of binding buffer had been added. The columns were placed into a 
collection tube, inverted and spun down at full speed for 30 seconds. The flow 
through was discarded while the column containing the stacked DNA was 
washed with 100µl wash buffer that was prepared by adding 24ml pure ethanol 
to 6ml wash buffer concentrate. The column was centrifuged again at high speed 
for 30 seconds. 
 
Desulfonation 
After washing, the converted DNA was desulfonated by adding 200µl 
desulfonation buffer to each column, incubation for 20minutes at room 
temperature and centrifugation at high speed for 30 seconds. Then, each column 
containing DNA was washed twice with 200µl wash buffer and spun down at high 
speed for 30 seconds.  
 
Elution 
For elution of the DNA, the columns were placed into fresh 1,5ml Eppendorf 
tubes, eluted by 12µl elution buffer and centrifuged at high speed for 30 seconds. 
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It was very important to proceeding immediate with further PCR to make the 
modified DNA stable for long term storage.  
2.3.4 Nested PCR – 1st Step 
The methylation status of the promoter region for p15INK4b tumor suppressor 
gene was determined by the method of MSP further modified as a nested two-
step approach in order to increase the sensitivity. For determining the 
methylation status of DAP kinase promoter region, MSP was performed without 
first step PCR amplification. The first step of nested PCR for p15INK4b was carried 
out with primer sets (forward and reverse) which were flanking the CpG-rich 
promoter regions of the p15INK4b gene. These extern primers (“p15-e”) did not 
discriminate between methylated and unmethylated nucleotides following sodium 
bisulfide conversion. 
 
P15-e-fw: 5´-GAYGTYGGTTTTTTGGTTTAGTTGA-3´ (VBC Genomics, HPLC-
purified) 
P15-e-rev: 5´-AACRCAACCRAACTCAAAACC-3´ (VBC Genomics, HPLC-
purified) 
Table 6: Nucleotide Sequences of Extern Primers of p15INK4b 
 
The first step PCR for p15INK4b was performed using 3µl (~100ng) of sodium 
bisulfite converted DNA and PCR Core Kit (Roche, 11578553001) containing 
10x buffer (100mM TrisHCl, 500mM KCl, pH8,3) , MgCl (25mM), dNTPs (10mM 
each), and Taq DNA Polymerase (250U; 5U/µl). The first step PCR Master Mix 
was prepared according to the manufacture´s protocol: 
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Components Stock Conc. Final Conc. 
Volume  
(for 1 rxn) 
A.bid.  - - 31,5µl 
DNTP-Mix 10mM 200µM 1µl 
10x PCR Buffer 10x 
(100mMTrisHCl, 
500mM KCl; 
pH8,3) 
1x (10mM 
TrisHCl, 50mM 
KCl) 
5µl 
Primer Mix  25µM p15-e-fw 
25µM p15-e-rev 
500nM fw 
500nM rev 
 
1µl 
MgCl 25mM 4mM 8µl 
TaqDNAPolymerase 5U/ul 2,5U 0,5µl 
DNA (Bisulfite 
converted) 
 
~33ng/ul 
 
~100ng 
 
3µl 
  Total Volume 50µl 
Table 7: Components for First Step PCR of p15-e 
 
The components of the PCR mix were added in the following order: 
 
Master Mix1 (amounts per sample): 
11,75µl  Aqua Bidest 
1µl   dNTPs 
1µl   Primermix (fw+rev) 
 
We put 13,75µl Master Mix1 into each 0,2ml Eppendorf PCR reaction tube 
before we added 3µl (~120ng) converted DNA or A. bid. 
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Master Mix2 (amounts per sample): 
19,75µl  Aqua Bidest 
5µl   10x PCR Buffer 
8µl   MgCl 
0,5µl   DNA-Polymerase 
 
Accordingly, we put 33,25µl Master Mix2 into each 0,2ml Eppendorf PCR 
reaction tube, resuspended the components with components of Master Mix1 via 
resuspension and placed the tubes into the icycler (Biorad). We performed the 
first step PCR according to the following cycle profile: 
 
HotStarTaq Activation 95°C 10min 
Denaturation 95°C 30sec  
40 CyclesAnnealing 56°C 30sec
Elongation 72°C 30sec
Final Elongation 72°C 8min 
Holding 4°C Hold 
Table 8: Cyling Conditions for First Step PCR in MSP for Amplification of p15 external 
gene region 
 
2% Agarose Gel 
The PCR-product of the p15 external region was 139bp in size. To detect the 
amplified DNA products we performed an agarose gel electrophoresis. 
Therefore, we used electrophoresis unit with 10-slot comb and prepared 750ml 
running buffer containing 1xTAE (Sigma, T9650). For 2% agarose gel we added 
2g Saekem Agarose (Sigma) to 100ml 1xTAE, boiled the solution in the 
microwave until it became translucent, added 10µl of 10 000xGelRed nucleic 
acid gel staining solution (Biotium, BIB 41003) and poured the agarose gel 
containing 1xGelRed into the electrophoresis chamber. After 40min gel had 
polymerized and we then removed comb and restraining bars from the chamber. 
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750ml of previously prepared 1xTAE running buffer was spilled into the 
electrophoresis chamber unit. Before DNA samples were loaded into the slots, 
each 25µl DNA sample was supplemented with 5µl of 5xgel loading buffer 
(Sigma, G2526). Furthermore, 1µl (1µg) 100bp-DNA –ladder (Promega, G176A) 
supplemented with 24µ Aqua Bidest and 5µl 5 x gel loading buffer was loaded 
into the first slot as size control. The gel ran at constantly 70V for 40min. The 
PCR products could be detected by intercalated GelRed which was seen as a 
band at 139bp. The gel was photographed with the Herolab Easy Gel 
Documentation System using adequate settings. PCR products of first step PCR 
were diluted 1:50 with Aqua Bidest and subjected to the second step of MSP. 
 
Figure 13: Example of First Step PCR Product of p15INK4b Extern Primers 
2.3.5 Real Time PCR using SYBR Green – 2nd step of nested PCR 
Another method to perform quantitative Real Time PCR without predisigned 
TaqMan probes and primers is to use SYBR Green detection system. SYBR 
Green intercalates into the DNA double helix (Zipper et al., 2004). In solution, 
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unbound SYBR Green exhibits very little fluorescence which is greatly enhanced 
upon DNA-binding. Thus, during PCR cycles, the increase in SYBR Green 
fluorescence at 530nm wavelength is directly proportional to the amount of 
generated double-strand-DNA. The basic steps are presented in Figure 14: 
 
1. The reaction mix contains optimized buffer, DNA, nucleotides, SYBR 
Green dye, and the primers complementary to the gene of interest. The 
unbound dye molecules weakly fluoresce and produce a minimal 
background fluorescence signal which is subtracted during computer 
analysis. 
2. At 95°C the double-stranded DNA denaturize into two single-stranded 
DNA strands 
3. When annealing temperature is achieved primers hybridize to the 
complementary sequences of the single stranded DNA only if the gene of 
interest is present. After annealing of the primers, a few SYBR Green 
molecules can intercalate to the double-stranded DNA. 
4. Emission of fluorescence is increased during elongation. 
5. More and more SYBR Green dye molecules can bind to the newly 
synthesized DNA. The fluorescence is increasing continuously. The 
measurement of the fluorescence is performed at the end of the 
elongation step of every PCR cycle to monitor the increasing amount of 
amplified DNA. 
6. During the following denaturation step of the next PCR cycle the SYBR 
Green molecules are released and the fluorescence signal of the dye falls. 
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Figure 14: Basic Steps of Quantitative Real Time PCR Based on SYBR Green Intercalation 
 
For quantitative methylation specific PCR we used primers which were 
synthesized by GenExpress and reagents from FastStart SYBR Green Master 
(Roche, 04673484001). The FastStart SYBR Green Master contained the 
FastStart Taq DNA Polymerase for hot start PCR which improved specificity and 
sensitivity of the PCR by minimizing the formation of non-specific products (Birch 
et al., 1996), dNTPs and an optimized buffer system. 
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The MSP contained primer sets for internal p15 unmethylated (p15-IU) or p15 
internal methylated (p15-IM) and DAP kinase internal unmethylated (DAPK-IU) 
or DAP kinase internal methylated (DAPK-IM) sequences that were designed to 
recognize bisulfite-induced modifications of unmethylated cytosines. Adequate 
sequences were taken from House et al., 2003 and Collins et al., 2006: 
 
Name/Symbol Sequence 
Product 
Size 
DAPK-IM fw 5´-GGATAGTCGGATCGAGTTAACGTC-3´  
98bp DAPK-IM rev 5´-CCCTCCCAAACGCCGA-3´ 
DAPK-IU fw 5´-GGAGGATAGTTGGATTGAGTTAATGTT-3´  
106bp DAPK-IU rev 5´-CAAATCCCTCCCAAACACCAA-3´ 
P15-IM fw 5´-GGTTTTTTATTTTGTTAGAGCGAGGC-3´  
68bp P15-IM rev 5´-TAACCGCAAAATACGAACGCG-3´ 
P15-IU fw 5´-GGTTGGTTTTTTATTTTGTTAGAGTGAGGT-3´  
80bp P15-IU rev 5´-AACCACTCTAACCACAAAATACAAACACA-3´ 
Table 9: Primer Sequences for SYBR Green Real Time RT-PCR 
 
We prepared the PCR Mix for Real Time PCR containing SYBR Green as 
following: 
 
Components Stock Conc. Final Conc. 
Volume 
(for 1 rxn)
SYBR Green Master 2x 1x 12,5µl 
PrimerMix (for U or M) 10µM rev 
10µM fw 
300nM rev 
300nM fw 
0,75µl 
Diluted DNA (1:50 from 1st step PCR 
for p15 or 1:20 from Bisulfite 
Conversion for DAP kinase) 
 ~100ng (p15) 
~10ng (DAPK) 
11,75µl 
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  Total Volume 25µl 
Table 10: Components for SYBR Green Real Time PCR Mix 
 
Finally, 11,75µl (~100ng for p15 or ~10ng for DAP kinase) of DNA template was 
added to 13,75µl of PCR mix into Eppendorf PCR reaction tubes and put into a 
thermocycler with sequence detection system (Corbett RotorGene Real Time 
Thermoanalyzer). We prepared triplicates for every sample and for controls. 
Every run was performed with primer sets complementary to methylated and 
conversed sequences of p15 or DAP kinase, negative controls containing no 
template to detect potential primer duplexes, and unmethylated human genomic 
DNA control. Thermal cycling conditions for all used primers and probes were as 
following: 
 
Activation of Hot StartTaq DNA Polymerase 95°C 10min Hold 
Denaturation 95°C 30sec  
50 Cycles Annealing 58°C 30sec
Elongation 72°C 30sec
Final Elongation 72°C 5min Hold 
Table 11: Cyling Conditions for SYBR Green Real Time PCR Amplification of p15INK4b 
methylated, p15INK4b unmethylated 
 
Activation of Hot StartTaq DNA Polymerase 95°C 10min Hold 
Denaturation 95°C 30sec  
50 Cycles Annealing 60°C 60sec
Elongation 72°C 60sec
Final Elongation 72°C 5min Hold 
Table 12: Cyling Conditions for SYBR Green Real Time PCR Amplification of DAP kinase 
methylated, and DAP kinase unmethylated 
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Analysis and Calculation of Gene Expression 
After the fiftieth cycle, a melting curve analyses was added to exclude detections 
of unspecific products. Sometimes the forward and the reverse primer built 
duplexes which were also detected by intercalation of SYBR Green leading to 
false positive values. During melting curve analysis, the thermo cycler 
accomplished a dissociation protocol that went through increasing temperatures 
and showed the melting temperature of the products. Normally, primer duplexes 
had a lower dissociation temperature as PCR products. Thus, identified samples 
containing unspecific primer duplexes were excluded from calculations. 
 
 
Figure 15: Example of a Melting Curve after SYBR Green Real Time PCR Amplification 
 
Analyzing the data from SYBR Green Real Time PCR firstly requires to view the 
amplification plot and to set the baseline and threshold values according to the 
manufacture´s protocol. The threshold value was set in an area in which a 
significant increase of signal was first detected.  
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Figure 16: Example of CT-Detection Curve Performing SYBR Green Real Time PCR 
Amplification 
 
Methylated gene expression was related to unmethylated gene expression. 
Methylation status of a gene was calculated by relating the CT values of control 
samples, which have been set at 1, to those of C75 or LY294002 treated cells. 
Unmethylated human genomic DNA was related to the solvent controls that have 
been set to 1. Means of triplicate determinations, mean standard deviations and 
Student´s TTESTs were calculated in Excel.  
2.4 Western blotting – Protein Analysis 
2.4.1 Treatment of the Cells  
We plated 6x105 A2780 cells per 60mm cell culture dish (Corning, NY, 430166). 
Cells were cultured in RPMI1640 supplemented with 5% FCS, 100U/ml 
Penicilline, 100µg/ml Streptomycine and 2mM L-Glutamine. We let them adhere 
over night before we started the treatment with 7µg/ml of C75, 40µM LY294002, 
15µg/ml Cycloheximide, the combination of 7µg/ml C75 with 15µg/ml 
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Cycloheximide (CHX), or the DMSO solvent control (0,0389% for C75 and 0,1% 
for LY294002 and 0,0539% for CHX+C75). We exposed the cells to the agents 
for indicated times at 37°C protected from light. Exactly 20minutes before 
homogenization we stimulated the cells with 100ng/ml epidermal growth factor 
(EGF) (Sigma, E9644). Then we checked the cell monolayer under the light 
microscope and noted confluence, morphology and apoptosis of the cells.  
2.4.2 RIPA Lysis 
Before lysis, media was removed and the monolayer was washed twice with cold 
PBS Dulbecco´s (Gibco, 14190-094). The remaining PBS was carefully removed 
with a yellow pipet tip. Cells were lysed in 80µl of freshly prepared RIPA+ lysis 
buffer (as described in Table 13 and Table 14) which was added per 60mm dish 
(1 confluent 60mm dish gives ~150 µg protein). 
 
Reagent MW 
Stock 
Concentration
Volume
Final 
Concentration
NaCl 58.44 5M 3ml 150mM 
Tris pH 7.4 121.14 1M 5ml 50mM 
DOC (Na-deoxycholate) 414.6 10% 5ml 0.5% 
EGTA 380.4 50mM 4ml 2mM 
EDTA, pH 7.4 372.2 50mM 10ml 5mM 
NaF 41.99 500mM 6ml 30mM 
ß-Glycerophosph.pH7.2 216 400mM 10ml 40mM 
Tetrasodium pyrophosph. 446.06 100mM 10ml 10mM 
Benzamidine 156.6 30mM 10ml 3mM 
Nonidet P-40  pure 1ml 1% 
Table 13: Ingredients for RIPA Lysis Buffer 
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The buffer was adjusted to pH 7,4, filled up with Aqua dest to 95ml and stored at 
4°C. RIPA+ was freshly prepared before use. 
 
Reagent Volume 
RIPA 1,90ml 
200mM Na-Orthovanadate 20µl 
25 x Complete stock solution (Protease Inhibitor Cocktail) 80µl 
Table 14: RIPA+ Lysis Buffer 
 
After adding 80 µl RIPA+, cells were left on ice for 5min and detached with a 
sterile scrapper. Then the lysates were transferred to an Eppendorf tube, 
vortexed for several times while incubating on ice and centrifuged for 30min at 
12.500rpm at 4°C. The pellet was discarded and the supernatant was saved at -
20°C for the protein assay.  
2.4.3 Protein Quantification 
We determined the protein concentration of each sample by BioRad Protein 
Assay Kit II (BioRad, 500-0112). This assay was performed in 96 well plates. 
First, a 10mg/ml BSA protein standard was produced by dissolving 10mg bovine 
serum albumine in 1ml Aqua dest. This protein standard was serially diluted 1:2 
with RIPA+ to obtain 5, 2.5, 1.25, 0.625, 0.3125, 0.15625 µg/µl protein 
standards. All protein standards were set up in a 96 well plate. RIPA+ was used 
as a blank control. We added triplicates of 5µl per well RIPA+, 5µl per well 
increasing protein standard concentrations or 5µl per well of protein sample into 
the plate. Reagent A’ of the Protein Assay Kit II was freshly prepared by adding 
1ml Reagent A (BioRad, 5000113) to 20µl Reagent S (BioRad, 5000115). 
Afterwards, 20µl Reagent A’ per well and 200µl Reagent B (BioRad, 5000114) 
per well were added to the probes and standards. After an incubation time of 
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20min the absorbtion was measured at 655/450 nm in the microplate reader 
(spectrophotometer Bio-Rad). The standard curve and protein concentrations 
were calculated using Excel. The protein samples were diluted to a concentration 
of 1,33 µg/µl with RIPA+ (3 parts) before 1 part of 4x sample buffer (Table 15) 
was added. The samples were adjusted to a final concentration of 1µg/µl in 1x 
sample buffer and stored at -20°C.  
 
Reagent MW Stock Volume
Final 
concentration 
Glycerol 92.09 pure 5 ml 50% 
Tris-HCl, pH 6.8 121.14 1M 1.25 ml 125mM 
SDS  20% 2,00 ml 4% 
Bromophenol blue  1% 1,25 ml 0,125% 
Beta-mercaptoethanol 
(added just before use) 
 pure 0.5ml 5% 
Table 15: Ingredients for 4 x Sample Buffer 
2.4.4 SDS- Polyacryl Amide Gel Electrophoresis (PAGE) 
In our experiments we analyzed proteins which were very different in size. The 
biggest protein was mTOR with 289kDa and the smallest protein was p15 with 
15kDa. Therefore we used gradient gels (Laborpartner, ID531s) to be able to 
detect a greater range of proteins on one gel. Nevertheless, we also poured 
7,5% SDS gels to detect proteins which were 40kDa to 90kDa in size. Thus, 
glass plates (Biorad, 1653308), spacers and gasket (Biorad, 1652904) were 
cleaned and assembled according to Bio-Rad instructions. Then, the 7,5% 
polyacryl amide separating gel was prepared (Table 16, Table 17 and Table 18). 
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Reagent Volume 
40% Acrylamid (BioRad, 1610140) 11,1 ml 
2%  Bis Solution (BioRad, 1610142) 3 ml 
Aqua bidest. 0,9 ml 
Total volume of 30 % A/B 15 ml 
Table 16: Preparation of 30% Acrylamide/Bis Solution 
 
Reagent Volume 
30% A/B (Table 16) 5 ml 
Aqua dest. 9,7 ml 
1,5M Tris 8,8 (BioRad, 1610798) 5 ml 
10% SDS (BioRad, 1610418) 200µl 
10% APS (BioRad, 1610700) 100µl 
Temed pur (BioRad, 1610800) 10µl 
Table 17: Separating Gel. Preparation of 7,5% Polyacryl amide gel 
 
The glass plates were filled with ~5ml separating gel (Table 17) and carefully 
overlayed with some Aqua bidest to remove any air bubbles. After 40 minutes 
the polyacryl amide was polymerized, Aqua bidest. was poured off and the comb 
was inserted. Then, the 4% polyacryl amide stacking gel solution was prepared 
(Table 18) and added to the very top of the separating gel. After ~30minutes the 
stacking gel was polymerized and combs were removed. 
 
Reagent Volume
30% A/B (Table 16) 1,673ml
Aqua bidest. 7,47ml 
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0,5M Tris 6,8 (BoiRad, 1610799) 3,15 ml 
10% SDS (BioRad, 1610418) 125µl 
10% APS (BioRad, 1610700) 125µl 
Temed pur (BioRad, 1610800) 12,5µl 
Table 18: Stacking Gel. Preparation of 4% Polyacryl amide gel 
 
The purchased plates including the gels or the self poured gels were inserted in 
the gel holder cassette (BioRad, 1703931) and the electrophoresis apparatus 
before 1x running buffer containing 25mM Tris, 192mM Glycine, and 0,1% SDS 
in Aqua bidest was added. First, the inner reservoir was filled with running buffer 
and checked for leak tightness before the outer reservoir was also filled with 1 x 
running buffer. Protein samples were boiled for 10 min at 95°C for denaturation. 
Then 20µg protein per sample was loaded into each slot. 1,5 µl of the molecular 
weight marker (Magic Mark XP from Invitrogen, LC5602) was loaded into the first 
lane of each gel without being boiled. The gel was run constantly at 100 Volt for 
~2 hours. After electrophoresis, the gel was subjected to Western blotting. 
2.4.5 Electrotransfer 
The separated proteins were transferred from the polyacryl amid gel onto a 
polyvinylidenedifluoride (PVDF) membrane (NEF, 153196). The precooled 
transfer buffer containing 150mM Glycine, 50mM Tris pH8,3, 0,05% sodium 
dodecylsulfate (SDS), and 20% Methanol was pured into the transfer chamber 
and a stirring rod was put inside to prevent heating during transfer. The 
membrane which was marked with a pen was shortly soaked in pure methanol 
before the blotting sandwich was assembled as shown in Figure 17. Scotch 
brites and filter papers were also soaked in transfer buffer. Air bubbles were 
removed by rolling a pipet fragment over the blotting sandwich. The 
electrotransfer was performed at constant 290mA overnight at 4°C in a cold 
room. 
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Figure 17: Assembly of Transfer Apparatus 
2.4.6 Immunostaining of the Blot Membranes 
The principle steps in immunostaining of western blots:  
 
1. Blocking of unspecific binding sides on the membrane 
2. Specific binding of the first antibody to the protein of interest.  
3. Binding of the horseradish peroxidise (HRP) conjugated secondary 
antibody to the first antibody 
4. Detection of proteins via HRP with enhanced chemiluminescense (Figure 
18). 
 
Between the individual steps many washing steps are performed. 
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Figure 18: Detection of Proteins by Chemoluminescence 
 
After disassembly of the transfer sandwich, the membrane was cut into the size 
of the gel by a razer blade. The first step in immunostaining was to block 
unspecific binding sides of the membrane. Therefore we prepared a blocking 
solution. The blocking solution contained 4% bovine serum albumin (BSA)(Fluka, 
05480) in 1 x Tris Buffer Saline (BioRad, 1706435, containing 0,1M Tris pH7,5, 
0,5M NaCl, Aqua dest) (TBS) supplemented with 0,1% Tween20 (BioRad, 
1706531) (TBS-T) and 4% heat inactivated fetal calf serum (Gibco, 10270-106). 
The membrane was incubated in 10ml blocking solution for 1hour at room 
temperature while shaking.  
During three washing steps in TBS-T each for 5minutes on the shaker at room 
temperature the first antibody solution was prepared. The first antibody solution 
consisted of 1 x TBS-T with 1% BSA and 0,05% Sodiumazide to make the 
antibody solution stable for longer storage. The specific first antibody binding the 
protein of interest was diluted 1:1000 (Table 19) with the first antibody solution 
and was incubated to the membrane at room temperature for 2 hours or over 
night at 4°C. After incubation, the membrane was washed twice for 5 minutes 
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and twice for 10 minutes in 1 x TBS-T on the shaker at room temperature to 
remove unspecific bindings of the first antibody. Then, the secondary antibody 
solution was prepared. The secondary antibody solution contained of 1 x TBS-T 
with 1% BSA in which an HRP conjugated antibody (Table 20) was diluted 
1:15000. This solution was freshly prepared before use and was incubated to the 
membrane for 1 hour at room temperature on the shaker. Afterwards, the 
membrane was washed twice for 5 minutes and twice for 10 minutes in 1 x TBS 
at room temperature on the shaker. For detection by enhanced 
chemiluminescence (ECL) the membrane was incubated with a mixture of 2ml 
Detection solution1 and 2ml Detection solution 2 (Pierce, 32106) which reacted 
with the horseradish peroxidise (HRP) conjugated to the secondary antibody. 
The protein of interest was then detected by exposing the membrane to an x-ray 
film (Hyperfilm ECL high performance chemiluminescence film, Amersham, 
RPN3103K) in the dark room. Every membrane was incubated at least with beta 
actin or tubulin as loading control.  
 
1stAntibody Dilution Feature Company Cat. No 
Size of 
target 
protein 
mTOR 1:1000 
rabbit 
polyclonal IgG
Cell Signaling 2972 289kDa 
phospho-mTOR 
(Ser2448) 
1:1000 
rabbit 
polyclonal IgG
Cell Signaling 2971 289kDa 
p70 S6 Kinase 1:1000 
rabbit 
polyclonal IgG
Cell Signaling 9202 70, 85kDa 
phospho-p70 S6 
Kinase 
(Thr421/Ser424) 
1:1000 
rabbit 
polyclonal IgG
Cell Signaling 9204 70, 85kDA 
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phospho-p70 S6 
Kinase (Thr389) 
1:1000 
rabbit 
polyclonal IgG
Cell Signaling 9205 70, 85kDa 
AKT1/2/3 1:1000 
rabbit 
polyclonal IgG
Cell Signaling 9272 60kDa 
phospho-
AKT(Ser473) 
1:1000 
rabbit 
polyclonal IgG
Cell Signaling 9271 60kDa 
P15 INK4B 1:1000 
rabbit 
polyclonal IgG
Cell Signaling 4822 15kDa 
4E-BP1  1:1000 
rabbit 
polyclonal IgG
Cell Signaling 9452 15-20kDa 
phospho-4E-BP1 
(Ser65)  
1:1000 
rabbit 
polyclonal IgG
Cell Signaling 9451 15-20kDa 
ERK1/2 1:1000 
rabbit  
polyclonal IgG
Cell Signaling 9102 42/44kDa 
phospho-ERK1/2 
(Thr202/Tyr204) 
1:1000 
rabbit 
polyclonal IgG
Cell Signaling 9101 42/44kDa 
Ubiquitin (P4D1) 1:1000 
mouse 
monoclonal 
IgG 
Cell Signaling 3936  
Alpha/beta 
Tubulin 
1:1000 
rabbit 
polyclonal IgG
Cell Signaling 2148 55kDa 
beta Actin 1:600 
goat 
polyclonal IgG
Santa Cruz 
Biotechnology
sc-1616 43kDa 
Table 19: First Antibodies 
 
2nd Antibody Dilution Feature Company Cat. No 
Donkey-anti-
rabbit  
1:15000 
horseradish 
peroxidase 
(HRP) linked 
Promega V795A 
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Donkey-anti goat  1:15000 
horseradish 
peroxidase 
(HRP) linked 
Santa Cruz 
Biotechnology 
sc2020 
Chicken-anti-
mouse 
1:15000 
horseradish 
peroxidase 
(HRP) linked 
Santa Cruz 
Biotechnology 
sc2954 
Table 20: Secondary Antibodies 
2.4.7 Stripping of Membranes 
After detection of a protein of interest it is possible to detach all antibodies from 
the protein and to incubate the blot with another antibody. Therefore we 
prepared a 1 x stripping solution containing 62,5mM Tris pH6,7 and 2%SDS and 
added 200µl ß-mercaptoethanol to 20ml of stripping solution. The blot was 
stripped for 20min at 50°C in a water-bath with frequent shaking. After stripping 
the membrane, the blot was washed 5 times for 5 minutes in TBS-T at room 
temperature on the shaker and blocked in blocking solution containing 4% FBS 
for 1 hour.  
2.4.8 Densitometry of the Protein Bands 
For quantification of the protein expression levels we performed densitometry 
using HeroLab software. Protein levels were estimated by relating the band of 
the specific antibody to that of beta actin. The antibody/actin ratios of treated 
samples were compared to those of vehicle-treated controls which have been set 
at 1 and the results were expressed in fold changes.  
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2.5 mRNA Gene Expression Array 
For gene expression profiling we used Affymetrix Human GeneChip Gene 1.0 ST 
Array System. This array interrogates the most up-to-date content of well-
annotated 28.869 genes with 764.885 distinct probes and was performed at 
Kompetenzzentrum für Fluoreszente Bioanalytik (KFB) in Heidelberg. They offer 
a complete solution for gene expression analysis that includes whole transcript 
sense target labeling, control reagents fluidics, scanning instrumentation and 
analysis. The Human Gene 1.0 ST Array uses a perfect match-only design with 
probes that hybridize to sense targets. The gene expression level of multiple 
probes on different exons is summarized into an expression value representing 
all transcripts from the same gene. Background is estimated using a set of 
~17.000 generic background probes and several standard poly-A controls and 
hybridization controls are represented on the array to allow troubleshooting.  
In fact, array analysis became a powerful approach for comparing RNA 
populations of treated and untreated cell cultures. The main steps performing an 
expression array involve: 
 
1. Isolation of RNA from the cells to be compared (performed by ourselves) 
2. Conversion of RNA to biotin-labeled cDNA by Reverse Transcription 
3. Hybridization of each labeled cDNA sample to a separate Chip 
4. Removal of unhybridized cDNA 
5. Staining of hybridized cDNA with a streptavidin-phycoerythrin conjugate 
6. Visualization with an array scanner and comparing the quantitative data 
from various samples 
 
The typical Affimetrix is a glass slide array that is produced using special 
methods which allow the nucleotides to be synthesized directly on the Chip 
substrate. For validation we additionally performed Real Time RT-PCR of several 
genes of interest. 
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Correlation analysis was also performed by KFB according to the manufacture´s 
protocol. To simplify the interpretation of the data, the correlation values were 
evaluated by Pearson´s Correlation or Spearman Rank Correlation, whereas 
they summarized the detection of the signal for each probe set to the median 
probe set signal of one gene. They normalized gene expression and generated 
relative Log Expression Signals (KFB, Affymetrix, data sheet).  
 
Array Format 169 
Feature Size 5µm 
Total Number of Distinct Probes 764.885 
Oligonucleotide Probe Length 25-mer probes 
Required Orientation of Labeled Targets to 
be Hybridized to the Array 
Sense 
Gene-level Probe Sets with Ensembl 
Support 
28.132 
Gene-level Probe Sets with Putative Full-
length Transcript Support (GenBank and 
RefSeq) 
19.734 
Estimated number of Genes 28.869 
Number of Probes per Gene (Resolution) ~26  
Genome Assembly 
March 2006 (USC Hg 18; NCBI 
build36) 
RefSeq NM Transcripts November 3, 2006 
GenBank putative full-length transcripts November 3, 2006 
Positive Controls (constitutively expressed 
genes) 
1.195 putative exon-level probe 
sets from putative constitutive 
genes 
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Negative Controls 
2.904 putative intron-level probe 
sets from putative constitutive 
genes 
Hybridization Controls bioB, bioC, bioD, cre 
Background Probes Antigenomic Set 
Poly-A Controls dap, lys, phe, thr 
Recommended Amount of Starting Material 100ng 
Acceptable Range of Input Amount 100ng-1µg 
Table 21: Specifications of Affymetrix Human GeneChip Gene 1.0 ST Array 
 
Our results only show an excerpt from the Affymetrix Human GeneChip Gene 
1.0 ST Array data. The genes were functional classified and revealed extensive 
changes in metabolism, cell survival, proliferation, transcription and degradation 
as a consequence of FASN inhibition. 
2.5.1 Treatment of Cells 
We plated 5,36x105 A2780 cells per tissue culture flask T25 (25cm2 growth area) 
or 16,08x105 cells per tissue culture flask T75 (75cm2 growth area). Cells were 
cultured in RPMI1640 supplemented with 5% FCS, 100U/ml Penicilline, 
100µg/ml Streptomycine and 2mM L-Glutamine. We let them adhere over night 
before we started the treatment with 7µg/ml of C75 or 0,0389%DMSO solvent 
control. Cells were exposed to the agents for 48hours at 37°C protected from 
light. Exactly 20minutes before homogenization we stimulated the cells with 
100ng/ml epidermal growth factor (EGF) (Sigma, E9644). Then we checked the 
cell monolayer under the light microscope and noted confluence, morphology 
and apoptosis of the cells. RNA was isolated from the cells (see chapter 2.2.2) 
and qualitative and quantitative controls were performed as described in chapter 
2.2.3. 100ng RNA was sent to KFB for Affymatrix Human GeneChip Gene 1.0 
ST Array analysis as described above.  
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3 Results 
3.1 Changes in mRNA levels resulting from FASN-
inhibition by C75 or from PI3K-inhibition by 
LY294002 in A2780 cells 
Up to date, a conclusive molecular explanation of the anti-proliferative and death 
promoting effects of FASN-inhibitors is still missing. In particular, the relationship 
between the FASN biochemical pathway and the epigenetic regulation of tumor 
suppressor genes is completely unexplored. First of all, we examined the mRNA 
expression levels of several tumor suppressor genes, apoptosis-related genes 
and epigenetically active enzymes in the ovarian cancer cell line A2780, which 
has been treated with the specific FASN-inhibitor C75 (7µg/ml) or the specific 
PI3K inhibitor LY294002 (40µM). Several types of tumors, including ovarian 
cancer, are known to have a hypermethylation phenotype (Esteller et al., 2001;  
Strathdee et al.,  2001). Therefore, we examined the gene expression status of 
some tumor suppressor genes, which have already been reported to be 
promoter hypermethylated.  
3.1.1 Changes in mRNA expression of tumor suppressor genes 
resulting from FASN-inhibition by C75 or PI3K-inhibition by 
LY294002 in A2780 cells 
The ovarian cancer cell line A2780 expresses high levels of FASN and its cell 
growth is sensitive to inhibition of FASN by C75. Growth data by Grunt et al. 
showed that best inhibition by C75 was achieved when A2780 had been treated 
with a concentration of 7µg/ml C75 (Grunt et al., 2009).Treatment times of 2,8 
(data not shown), 24, 48,72 hours were chosen to capture early and late gene 
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changes associated with the block of cell cycle progression and the advent of 
apoptosis occurring in response to inhibition of FASN by C75. Results were 
examined in three biological experiments. The mRNA expression was 
normalized to ß-actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
and compared to the solvent control of C75 for every time point. 
Correspondingly, cells were exposed to 40µM LY294002 for the same time 
periods and mRNA expression was analyzed as described for C75. 
3.1.1.1 C75 and LY294002 increase p15INK4b mRNA expression level in 
A2780 cells 
In A2780,  C75 significantly enhances mRNA expression level of p15INK4b in 
three replicates. Inactivation of FASN elevates the transcript level of p15INK4b 5,6-
fold after 24 hours of exposure to 7µg/ml C75, 6,8-fold after 48 hours of 
exposure and 7,9-fold after 72 hours of exposure. This indicates that treatment of 
A2780 cells with 7µg/ml C75 induces a time-dependent elevation of the gene 
expression level of this inhibitor of cyclin-dependent kinases that prevents the 
cell from going through the G1-S phase transition (Figure 19). However, our data 
suggest that this effect is more pronounced on the mRNA than on the protein 
level and actually cannot have further implication on the cell cycle as the protein 
level of p15 is even reduced in C75-treated A2780 (Figure 31, later time points). 
Since FASN-inhibition has been reported to block the PI3K/AKT pathway (Grunt 
et al., 2009) we also used LY294002 in a concentration of 40µM as a PI3K 
inhibitor in A2780 to compare the changes on several tumor suppressor genes. 
LY294002 exerts similar effects on p15INK4b mRNA expression in A2780 as 
compared to C75. Both compounds augment the gene expression level of this 
cyclin-dependent kinases inhibitor while C75 seems to be more effective in 
promoting p15INK4b mRNA expression. C75-treated cells show a maximum of 7,9-
fold stimulation in p15INK4b mRNA expression after 72 hours of treatment and 
LY294002-treated cells reveal a maximal 5.5-fold increase in p15INK4b transcript 
level after 72 hours of exposure (Figure 19). As already seen in C75-treated 
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cells, LY294002 incubated cells also show an increase in mRNA expression of 
p15INK4b but no change in p15INK4b protein level (Figure 32). Therefore both 
substances do not seem to block the cell cycle in A2780 cells by the cyclin-
dependent kinase inhibitor p15INK4b though a significant increase in its mRNA 
expression is observed (Figure 19). 
 
Figure 19: Inhibition of FASN or PI3K increases mRNA expression of cyclin-dependent 
kinase inhibitor p15INK4b.  
Quantitative Real Time RT-PCR was done on A2780 cells. Cells were treated with 7µg/ml 
C75 or 40µM LY294002 for 24, 48, or 72 hours. mRNA expression was determined relative 
to vehicle-treated controls (“solvent control”). Statistical significance between inhibitor- 
and vehicle-treated solvent controls was determined by two-tailed Student´s t-test, * 
indicates significant difference at p<0,05, ** indicates significant difference at p<0,01, and 
*** indicates significant difference at p<0,001.  
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3.1.1.2 C75 and LY294002 decrease p16INK4a mRNA expression level in 
A2780 cells 
Neither FASN inhibition by C75 nor blocking of PI3K by LY294002 enhance the 
mRNA expression level of p16INK4a in A2780 after 24 hours of treatment. Instead, 
they rather decrease the p16INK4a mRNA level. Strongest down-regulation to 0,4-
fold is seen after 72 hours of treatment with LY204002 and a 0,6-fold change 
appeared after 72 hours of incubation with C75 (Figure 20). This suggests that in 
A2780 the cyclin dependent kinase inhibitor p16INK4a is not responsible for cell 
cycle blockade in G1 caused by FASN or PI3K inhibition.  
 
Figure 20: Inhibition of FASN or PI3K decreases mRNA expression of cyclin-dependent 
kinase inhibitor p16INK4b.  
Quantitative Real Time RT-PCR was done on A2780 cells. Cells were treated with 7µg/ml 
C75 or 40µM LY294002 for 24, 48, or 72 hours. mRNA expression was determined relative 
to vehicle-treated controls (“solvent control”). Statistical significance between inhibitor- 
and vehicle-treated solvent controls was determined by two-tailed Student´s t-test, * 
indicates significant difference at p<0,05, ** indicates significant difference at p<0,01, and 
*** indicates significant difference at p<0,001. 
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3.1.1.3 C75 and LY294002 increase E-Cadherin mRNA expression level in 
A2780 
After 24 hours of treatment, the E-Cadherin mRNA expression level is not 
significantly modulated by C75 nor by LY294002. However, at later time points 
both compounds significantly elevate the CDH1 gene expression level in A2780 
cells (Figure 21). LY294002 upregulates E-Cadherin mRNA 7,2-fold after 48 
hours of treatment, which increases further to 10,2-fold after 72 hours of 
incubation (Figure 21). 
C75 shows similar, but less pronounced effects. After 48 and 72 hours of 
treatment the gene expression level of E-Cadherin increases 4,2-fold and 4,4-
fold, respectively (Figure 21). These results indicate that both compounds can 
modulate the adhesion specificity. This effect may be utilized in anticancer 
strategies by specific molecular targeting of invasion and metastasis processes 
in ovarian cancer. 
 
Figure 21: Inhibition of FASN or PI3K increases mRNA expression of the tumor 
suppressor gene CDH1.  
Quantitative Real Time RT-PCR was done on A2780 cells. Cells were treated with 7µg/ml 
C75 or 40µM LY294002 for 24, 48, or 72 hours. mRNA expression was determined relative 
to vehicle-treated controls (“solvent control”). Statistical significance between inhibitor- 
and vehicle-treated solvent controls was determined by two-tailed Student´s t-test, * 
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indicates significant difference at p<0,05, ** indicates significant difference at p<0,01, and 
*** indicates significant difference at p<0,001. 
3.1.1.4 C75 and LY294002 increase Death Associated Protein Kinase 
(DAPK, DAP-2) mRNA expression level in A2780 cells 
In A2780 the DAPK mRNA expression level is markedly enhanced in a time 
dependent manner by LY294002 as well as by C75 (Figure 22). Cells incubated 
with LY294002 for 24 hours show 3,4-fold increase in gene expression level and 
after 48 hours of treatment with LY294002 the DAP-2 mRNA transcription is 
stimulated 3,8-fold. The most significant augmentation can be seen after 72 
hours of incubation with LY294002 when the gene expression level of DAPK is 
elevated 6,3-fold. In C75 treated cells the mRNA level of DAPK is increased 2-
fold after 24 hours, 5,9-fold after 48 hours and peaks at 6,7-fold after 72 hours of 
exposure (Figure 22).  
 
Figure 22: Inhibition of FASN or PI3K increases mRNA expression of the tumor 
suppressor gene DAPK.  
Quantitative Real Time RT-PCR was done on A2780 cells. Cells were treated with 7µg/ml 
C75 or 40µM LY294002 for 24, 48, or 72 hours. mRNA expression was determined relative 
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to vehicle-treated controls (“solvent control”). Statistical significance between inhibitor- 
and vehicle-treated solvent controls was determined by two-tailed Student´s t-test, * 
indicates significant difference at p<0,05, ** indicates significant difference at p<0,01, and 
*** indicates significant difference at p<0,001. 
3.1.2 Changes in mRNA expression level of apoptosis 
associated genes resulting from FASN-inhibition by C75 or 
PI3K-inhibition by LY294002 in A2780 cells 
3.1.2.1  C75 and LY294002 increase FAS mRNA expression level in A2780 
cells 
While LY294002 upregulates FAS mRNA in A2780 only moderately to a 
maximum of 2,3-fold normalized to LY294002 solvent control after 72 hours of 
treatment, C75 significantly enhances FAS mRNA expression in a time 
dependent manner up to 97,9-fold after 72 hours of treatment. Even at earlier 
time points of C75 treatment the FAS gene expression is strongly augmented, 
7,9-fold after 24 hours and 12,5-fold after 48 hours of C75 incubation (Figure 23). 
This suggests that FASN blockade stimulates not only stress associated 
apoptosis (Knowles et al., 2008) and mitochondrial associated apoptosis (Kawai 
et al., 1999), but, in contrast to LY294002, it foremost triggers TNF-α-dependent 
apoptosis process. 
 Results 
 76 
 
Figure 23: FASN inhibitor increases mRNA expression of death associated FAS more 
significantly than PI3K inhibitor.  
Quantitative Real Time RT-PCR was done on A2780 cells. Cells were treated with 7µg/ml 
C75 or 40µM LY294002 for 24, 48, or 72 hours. mRNA expression was determined relative 
to vehicle-treated controls (“solvent control”). Statistical significance between inhibitor- 
and vehicle-treated solvent controls was determined by two-tailed Student´s t-test, * 
indicates significant difference at p<0,05, ** indicates significant difference at p<0,01, and 
*** indicates significant difference at p<0,001. 
3.1.2.2 C75 and LY294002 increase manganese Superoxid Dismutase 
(MnSOD, SOD2) mRNA expression level in A2780 cells 
LY294002 enhances SOD2 gene expression in A2780 only marginally after 24 
and 48 hours treatment (1,4 and 1,3-fold, respectively). After 72 hours of 
incubation with LY294002, SOD2 gene expression was elevated 2-fold. On the 
contrary, C75-treated A2780 reveal rapid and strong upregulation of SOD2 
mRNA. At 24 hours of C75 treatment no modulation is seen, whereas at 48 
hours a significant 2-fold increase and at 72 hours a 2,7-fold change is observed 
(Figure 24).  
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Figure 24: FASN inhibition increases mRNA expression of MnSOD2 more significantly 
than PI3K inhibition.  
Quantitative Real Time RT-PCR was done on A2780 cells. Cells were treated with 7µg/ml 
C75 or 40µM LY294002 for 24, 48, or 72 hours. mRNA expression was determined relative 
to vehicle-treated controls (“solvent control”). Statistical significance between inhibitor- 
and vehicle-treated solvent controls was determined by two-tailed Student´s t-test, * 
indicates significant difference at p<0,05, ** indicates significant difference at p<0,01, and 
*** indicates significant difference at p<0,001. 
3.1.3 Changes in mRNA expression level of epigenetically active 
enzymes resulting from FASN-inhibition by C75 or PI3K-
inhibition by LY294002 in A2780 cells 
Hypermethylated CpG islands of silenced tumor-suppressor genes are 
characterized overall by histone hypoacetylation and histone methylation 
(Esteller et al.  2007). We hypothesized that demethylation by C75 could be 
responsible for transcription stimulation of some tumor suppressor genes as 
many of them have already been reported to be promoter hypermethylated. 
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Aberrant methylation of CpG islands in promoter regions of p15INK4b (Herman et 
al., 1996) and p16INK4a (Katsaros et al., 2004) as well as gene methylation of 
DAPK (Collins et al., 2006) and CDH1 (Rathi et al., 2002; Makerla et al., 2005) 
have been observed. After having demonstrated that FASN inhibition 
upregulates the transcript levels of p15, E-Cadherin, DAPK, SOD2 and FAS in 
the ovarian carcinoma cell line A2780 we examined the effects of FASN 
targeting on the expression of epigenetically active enzymes and found some 
inhibitor-dependent regulations of these enzymes arguing for a possible 
epigenetic mechanism of action of this FASN blocking drug. Modulation of 
epigenetically active enzymes is expected to occur before transcriptional 
changes of affected tumor suppressor genes become evident. Therefore, 
examination of C75-effects on mRNA expression of epigenetically active 
enzymes was focused on earlier time points of C75 treatment.  
3.1.3.1 C75 and LY294002 decrease DNA-methyltransferase 1 (DNMT1) 
mRNA expression level after 24 hours of treatment 
At 24 hours, C75 inhibits DNMT1 mRNA expression 0,4-fold, whereas LY294002 
exerts a weaker effect repressing DNMT1 mRNA 0,7-fold relative to solvent 
control. At later time points, C75 fails to down-regulate DNMT1, whereas 
LY294002 even enhances DNMT1 mRNA (Figure 25). Although DNMT1 is 
known as a basic DNMT it has been reported to be also involved in de novo 
methylation (Esteller et al., 2007). Our data thus indicate that FASN inhibition by 
C75 reduces transcription of this potent methylating enzyme hours before mRNA 
expression of some of the potentially hypermethylated tumor suppressor genes 
such as E-Cadherin and DAPK is increased. 
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Figure 25: Inhibition of FASN or PI3K decreases DNMT1 mRNA expression level after 24 
hours of treatment.  
Quantitative Real Time RT-PCR was done on A2780 cells. Cells were treated with 7µg/ml 
C75 or 40µM LY294002 for 24, 48, or 72 hours. mRNA expression was determined relative 
to vehicle-treated controls (“solvent control”). Statistical significance between inhibitor- 
and vehicle-treated solvent controls was determined by two-tailed Student´s t-test, * 
indicates significant difference at p<0,05, ** indicates significant difference at p<0,01, and 
*** indicates significant difference at p<0,001. 
3.1.3.2 C75 and LY294002 increase DNMT3a mRNA expression level in 
A2780 cells 
We also examined the effects of C75 and LY294002 on DNMT3a mRNA level. 
Both compounds augment DNMT3a mRNA at 24, 48 and 72 hours of exposure 
(Figure 26). The modulation of tumor suppressor gene mRNA expression levels 
gives us just very indecisive information about methylating activities since the 
entire epigenetic machinery not only targets these genes. Therefore, DNMT3a 
probably targets at other genes that do not exert tumor suppressor functions. 
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Figure 26: Inhibition of FASN or PI3K increases DNMT3a mRNA expression.  
Quantitative Real Time RT-PCR was done on A2780 cells. Cells were treated with 7µg/ml 
C75 or 40µM LY294002 for 24, 48, or 72 hours. mRNA expression was determined relative 
to vehicle-treated controls (“solvent control”). Statistical significance between inhibitor- 
and vehicle-treated solvent controls was determined by two-tailed Student´s t-test, * 
indicates significant difference at p<0,05, ** indicates significant difference at p<0,01, and 
*** indicates significant difference at p<0,001. 
3.1.3.3 C75 and LY294002 decrease DNMT3b mRNA expression level in 
A2780 cells 
DNMT3a mRNA is down-regulated neither by LY294002 nor by C75 in A2780. 
Nevertheless, both agents decrease DNMT3b transcripts at 24 and 48 hours, 
and C75 at 72 hours as well (Figure 27). Thus, our data on DNMT1 and 
DNMT3b suggest that pharmacological FASN blockade exerts inhibiting effects 
on the methylation machinery, whereas the activity of PI3K inhibition is less 
consistent. 
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Figure 27: Inhibition of FASN or PI3K decreases DNMT3b mRNA expression level.  
Quantitative Real Time RT-PCR was done on A2780 cells. Cells were treated with 7µg/ml 
C75 or 40µM LY294002 for 24, 48, or 72 hours. mRNA expression was determined relative 
to vehicle-treated controls (“solvent control”). Statistical significance between inhibitor- 
and vehicle-treated solvent controls was determined by two-tailed Student´s t-test, * 
indicates significant difference at p<0,05, ** indicates significant difference at p<0,01, and 
*** indicates significant difference at p<0,001. 
3.1.3.4 C75 and LY294002 do not down-regulate histone deacetylase 2 
(HDAC2) mRNA in A2780 cells 
After 24 hours of exposure to LY294002 or to C75 HDAC2 mRNA remains 
essentially unaffected. Moreover, at later time points, LY294002 and C75 rather 
up-regulate HDAC2 than reducing it (Figure 28). Histone deacetylases are 
known to repress transcription of methylated DNA of many tumor suppressor 
genes. The effects of C75 and LY294002 on the epigenetic machinery of A2780 
cells thus remain controversial. Moreover, the epigenetic regulation does not act 
very specifically. Thus many genes can be targeted and it is still not clear how 
genes are chosen for methylation silencing. 
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Figure 28: Inhibition of FASN or PI3K increases mRNA expression of HDAC2.  
Quantitative Real Time RT-PCR was done on A2780 cells. Cells were treated with 7µg/ml 
C75 or 40µM LY294002 for 24, 48, or 72 hours. mRNA expression was determined relative 
to vehicle-treated controls (“solvent control”). Statistical significance between inhibitor- 
and vehicle-treated solvent controls was determined by two-tailed Student´s t-test, * 
indicates significant difference at p<0,05, ** indicates significant difference at p<0,01, and 
*** indicates significant difference at p<0,001. 
3.2 Changes in methylation status of tumor suppressor 
genes resulting from FASN-inhibition by C75 or 
PI3K-inhibition by LY294002 in A2780 cells 
After having demonstrated that both FASN and PI3K inhibition increase the 
mRNA expression levels of p15INK4b and DAPK, which both are reported to be 
promoter hypermethylated in ovarian cancer (Collins et al., 2007; Liu et al., 1, 
2005), we examined the methylation status of these two genes after C75 or 
LY294002 treatment using methylation-specific PCR. A control sample 
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containing semi-methylated genomic DNA from healthy tissue was also included 
in the analyses. 
3.2.1 The promoter of the p15INK4b tumor suppressor gene is not 
hypermethylated in A2780 cells 
The genomic DNA control which should not exhibit hypermethylation in any 
tumor suppressor gene reveals higher methylation of p15INK4b than treated or 
untreated A2780 at any time point. This indicates that the ovarian carcinoma cell 
line A2780 does not feature a hypermethylation status in the promoter region of 
p15INK4b (Figure 29). After having demonstrated that there is no hypermethylation 
of the p15INK4b gene promoter region in A2780, no further demethylation can 
obviously be achieved with C75 or with LY294002 (Figure 29).  
Although a hypermethylated phenotype in ovarian cancer has often been 
reported (Collins et al., 2007;  Liu et al., 1, 2005) we could not show this 
methylation status for the promoter of p15INK4b in the A2780 cell line. This 
indicates that upregulation of p15INK4b mRNA expression must occur via 
mechanisms that are not related to gene promoter demethylation.  
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Figure 29: Analysis of the methylation status of the p15INK4b promoter region.  
As demonstrated by quantitative methylation-specific PCR (Q-MSP) no promoter 
hypermethylation of p15INK4b was observed in A2780. Cells were treated with 7µg/ml C75 or 
40µM LY294002 for 24, 48, or 72 hours. Methylation status was determined relative to 
vehicle-treated controls (“solvent control”). Statistical significance between inhibitor- and 
vehicle-treated solvent controls was determined by two-tailed Student´s t-test, * indicates 
significant difference at p<0,05, ** indicates significant difference at p<0,01, and *** 
indicates significant difference at p<0,001. 
3.2.2 C75-mediated upregulation of DAPK mRNA correlates with 
demethylation of the hypermethylated gene promoter 
Our results show that the methylation status of the DAPK promoter region in 
untreated A2780 cells is five times higher when compared to the methylation 
level found in a genomic DNA control sample. Treatment of A2780 with C75 
time-dependently decreases methylation of the DAPK promoter. As soon as 2 
hours after addition of C75 the methylation level of DAPK decreases by 50% 
when compared to solvent control. C75-mediated DAPK demethylation proceeds 
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to reach normal levels after 48 hours. At 72 hours the promoter is almost 
completely demethylated (Figure 30). This suggests that FASN blockade by C75 
modulates expression of this tumor suppressor gene by epigenetic mechanisms. 
This provides another molecular explanation for the observed anti-proliferative 
and death promoting effects of FASN-inhibitors. Importantly, until now the 
relationship between FASN biochemical pathways and epigenetic regulation of 
tumor suppressor genes has been completely unexplored. Therefore, this is the 
first report demonstrating molecular links between FASN-mediated lipogenesis 
and epigenetic modulation of tumor suppressor gene expression in (cancer) 
cells. 
 
Figure 30: Analysis of the methylation status of the DAPK promoter region using 
quantitative methylation-specific PCR (Q-MSP).  
A2780 cells were treated with 7µg/ml C75 for 2, 48, or 72 hours. Methylation status was 
determined relative to vehicle-treated controls (“solvent control”). Statistical significance 
between inhibitor- and vehicle-treated solvent controls was determined by two-tailed 
Student´s t-test, * indicates significant difference at p<0,05, ** indicates significant 
difference at p<0,01, and *** indicates significant difference at p<0,001. 
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3.3 The FASN targeting drug C75 affects protein 
expression and activity (phosphorylation) of 
PI3K/AKT effector molecules 
The expression of cyclin-dependent kinase inhibitors (CDKIs) is reported to be 
regulated at least in part by the PI3K/AKT signaling pathway (Gao et al., 2004; 
Katayama et al., 2008). After having demonstrated that FASN inhibition 
increases mRNA expression of the CDKI p15INK4b in A2780 without inducing 
demethylation of the corresponding promoter we therefore examined the effects 
of C75 on the protein expression and activation (phosphorylation) of PI3K/AKT 
signaling molecules. Modulation of the PI3K/AKT pathway by FASN inhibition in 
ovarian carcinoma cell lines has already been observed (Grunt et al., 2009; 
Wang  et al., 2005) and the PI3K activity is known to be required for ovarian 
cancer cell proliferation and G1 cell cycle progression (Gao et al., 2004; 
Katayama et al., 2008). Thus, we treated A2780 with the FASN inhibitor C75 
followed by immunoblot analysis of AKT, phospho-AKT, mTOR, phospho-mTOR, 
p70S6K, phospho-p70S6K, 4eBP1, phospho-4eBP1, ERK1/2 and phospho-
ERK1/2 to examine the molecular interaction between FASN, PI3K/AKT 
signaling, and the CDKI p15INK4b.  
3.3.1 Reduction of protein expression and phosphorylation of 
PI3K/AKT signaling molecules by the FASN inhibitor C75 
At first, we examined the p15 protein level in A2780 after treatment with C75. 
Unexpectedly, we were  unable to detect an increase of p15 protein level, which 
would correspond to our mRNA expression data, rather we obtained a slight 
decrease of p15INK4b upon C75 exposure indicating that p15INK4b is (post-) 
translationally modulated by C75 (Figure 31A). Either p15INK4b mRNA translation 
is affected or p15INK4b protein is post-translationally destabilized. Importantly, this 
data, which is conflicting with our observation that C75 stimulates p15INK4b mRNA 
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expression, indicates that this CDKI is not responsible for the G1 arrest caused 
by FASN blockade (Knowles et al., 2004).  
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Figure 31: FASN inhibition reduces phosphorylation and expression of p15INK4b, ERK1/2 
and PI3K downstream signaling proteins.  
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A, A2780 cells were treated with vehicle (0,0389% DMSO) or C75 (7µg/ml) for the indicated 
times. Except from one untreated sample in Figure 31, all cells were stimulated for 20 
minutes with 100ng/ml EGF. Cell lysates were collected as described in Materials and 
Methods for immunoblot analysis with specific antibodies for AKT, phospho-AKT 
(Ser473), mTOR, phospho-mTOR(Ser2448), p70S6K, phospho-p70S6K (Thr389 or 
Thr421/Ser424), p15INK4b, 4eBP1, phospho-4eBP1 (Ser65), ERK1/2, phospho-ERK1/2 
(Thr202/Tyr204), and ß-actin. Experiments were quantified using Herolab Software by 
measuring the optical density of the band specific for the respective protein of interest 
relative to that of ß-actin. Values of treated samples were then related to those of solvent 
control samples. B, specific phosphorylation level of each protein was quantified using 
the Herolab Software by relating the phospho-protein/ß-actin ratio to the corresponding 
protein/ß-actin ratio. The resulting value for the solvent control was arbitrarily set at 1 for 
each time point and the value for the corresponding C75-treated cells was related to it. 
Due to bad quality of the blot it was not possible to calculate the 72 hours time point for 
specific phosphorylation of mTOR. 
 
Nevertheless, C75 downregulates expression and phosphorylation of signal 
effector proteins of the PI3K/AKT pathway such as AKT, mTOR, p70S6K and 
4eBP1 in A2780 cells (Figure 31A, B). Interestingly, C75 pre-treatment inhibits 
AKT, mTOR, p70S6K and 4eBP1 phosphorylation elicited by EGF (100ng/ml) 
and simultaneously decreases the corresponding protein levels. In contrast, 
phospho-ERK1/2 levels slightly increase upon C75 treatment (Figure 31B), even 
though total ERK1/2 protein expression slightly declines at later time points of 
exposure (Figure 31A). Enhancement of ERK1/2 phosphorylation is also 
observed in LY294002 treated A2780 (Figure 32B). Unlike FASN inhibition by 
C75, the PI3K inhibitor LY294002 does not markedly lower the expression levels 
of several PI3K/AKT signaling proteins (Figure 31A, Figure 32A). Nevertheless, 
both drugs efficiently lower phosphorylation of the proteins (Figure 31B, Figure 
32B). This data indicate that C75-mediated blockade of FASN reduces the 
activity of the PI3K cascade even though C75 is not that effective in inhibiting 
protein phosphorylation as compared to the specific PI3K inhibitor LY294002. In 
contrast, our results demonstrate that inactivation of AKT signaling by LY294002 
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or C75 concurrently slightly activates ERK1/2 in A2780. Moreover, C75 seems to 
decrease the total protein level of all signal proteins analyzed, whereas 
LY294002 does not down-regulate or even elevates signal protein expression 
(Figure 32A).  
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Figure 32: PI3K inhibition by LY294002 is more effective in blocking the PI3K pathway than 
FASN inhibition.  
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A, A2780 cells were treated with vehicle (0,1% DMSO) or LY294002 (40µM) for the indicated 
times. Except from one untreated sample in Figure 32, all cells were stimulated for 20 
minutes with 100ng/ml EGF. Cell lysates were collected as described in Materials and 
Methods for immunoblot analysis with specific antibodies for AKT, phospho-AKT 
(Ser473), mTOR, phospho-mTOR(Ser2448), p70S6K, phospho-p70S6K (Thr389 or 
Thr421/Ser424), p15INK4b, 4eBP1, phospho-4eBP1 (Ser65), ERK1/2, phospho-ERK1/2 
(Thr202/Tyr204), and ß-actin. Experiments were quantified using Herolab Software by 
measuring the optical density of the band specific for the respective protein of interest 
relative to that of ß-actin. Values of treated samples were then related to those of solvent 
control samples. B, specific phosphorylation level of each protein was quantified using 
the Herolab Software by relating the phospho-protein/ß-actin ratio to the corresponding 
protein/ß-actin ratio. The resulting value for the solvent control was arbitrarily set at 1 for 
each time point and the value for the corresponding C75-treated cells was related to it. 
3.3.2 Reduction of protein expression levels caused by FASN 
inhibition appears not to be due to translation inhibition by 
dephosphorylated 4eBP1 
C75-mediated blockade of 4eBP1 phosphorylation (Figure 31B) results in 
enhanced binding of 4eBP1 to elF4E thus preventing eIF4E from binding to 
eIF4F complex and supporting protein translation. This might explain our 
observation that the steady-state levels of all signaling proteins were reduced by 
C75 in A2780 cells.  
In contrast to many of the PI3K downstream proteins analyzed in this study, the 
protein level of ß-actin which is transcribed from a “strong” mRNA and is 
therefore known to be insensitive to alterations of eIF4E availability (Graff et al.,  
2008), did not decrease. However, AKT and p70S6K decreased before the 
blocking activity through dephosphorylated 4eBP1 has been established (Figure 
31, earlier time points). Therefore, downregulation of signaling proteins can only 
partially be explained by 4eBP1 bindings of eIF4E. Moreover, if C75-mediated 
blockade of 4eBP1 phosphoylation would be responsible for a translational 
blockade of the analyzed proteins, the LY294002-induced complete inhibition of 
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4eBP1 phosphorylation would have led to the disappearance or at least to a 
marked decrease of these proteins as well. However, this is not the case (Figure 
32). Therefore, we can exclude that C75-mediated prevention of 4eBP1 
phosphorylation and thus the consequent decreased eIF4F complex formation 
and protein translation is the cause for protein level reduction of AKT, mTOR, 
p70S6K, 4eBP1, p15INK4b and ERK1/2 in A2780. 
3.3.3 Reduction of protein expression caused by FASN 
inhibition appears to be due to enhanced protein 
degradation 
To further elucidate the possible mechanism of C75-dependent reduction of 
signal protein expression we performed western blot analyzes on samples that 
have been pretreated with cycloheximide (15µg/ml), a potent translation inhibitor, 
and C75 (7µg/ml) seperately or in combination. The half-life (IT50) of each 
PI3K/AKT signaling protein analyzed was reduced significantly by C75 (Figure 
33) indicating that FASN inhibition by C75 causes enhanced protein degradation. 
Cycloheximide single treatment (15µg/ml) downregulates AKT protein level in 
A2780 with an IT50 of 48 hours. This time indicates the normal degradation time 
of 50% of this protein without being newly synthesized. Co-exposure of the cells 
to cyclohehimide and C75 decreased the IT50 for AKT protein to 19 hours 
(Figure 33, B). Similar effects were seen for all analyzed proteins of the 
PI3K/AKT cascade (Figure 33). However, the greatest C75-mediated 
degradation effect was seen for p15. With cycloheximide alone the IT50 of 
p15INK4b was 57 hours. This value was shortened by coexposure to C75 as low 
as 18 hours. Our data thus suggest that C75 elevates p15INK4b protein 
degradation, whereas it concurrently stimulates p15INK4b mRNA expression.  
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Figure 33: FASN inhibition enhances protein degradation.  
A, A2780 cells were treated with vehicle, C75 (7µg/ml), cycloheximide (15µg/ml), or with 
C75 combined with cycloheximide for the indicated times. Except from one untreated 
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sample, all cells were stimulated for 20 minutes with 100ng/ml. Cell lysates were collected 
as described in Materials and Methods for immunoblot analysis with antibodies specific 
for AKT, mTOR, p70S6K, p15INK4b, 4eBP1, ERK1/2, ß-actin and α/ß-tubulin. B, Experiments 
were quantified by relating the optical density of the band of the protein of interest to that 
of ß-actin. For each time point the resulting ratios of the sample treated with 
cycloheximide and C75 seperately or in combination were related to the vehicle control, 
which was arbitrarily set at 1. 
3.3.4 Reduction of protein expression caused by FASN 
inhibition appears to be due to enhanced proteasomal 
protein degradation 
After having demonstrated that FASN inhibition by C75 augments protein 
degradation of AKT, mTOR, p70S6K, 4eBP1, p15INK4b and ERK1/2, we then 
asked whether this might correlate with altered function of the proteasome. 
Therefore, A2780 cells were treated with 7µg/ml C75 for the indicated periods of 
time followed by immunoblot analysis of ubiquitin-modified proteins. As 
expected, FASN inhibition induced accumulation of ubiquitinated proteins (Figure 
34A, C). In contrast, inhibition of PI3K rather decreased protein ubiquitination 
than increasing it (Figure 34B, C). This correlates with slightly enhanced protein 
levels of several PI3K signaling proteins as demonstrated in Figure 32A. Most 
importantly, the time-courses of C75-induced protein ubiquitination and C75-
mediated reduction of signal protein and p15INK4b protein expression closely 
conform to each other (Figure 31, Figure 34, C) supporting the hypothesis that 
FASN activity is involved in the functionality of the proteasomal pathway via a 
molecular crosstalk between FASN and proteasome pathways.  
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Figure 34: Fatty acid synthase and proteasome pathways crosstalk with each other.  
A, A2780 cells were treated with C75 (7µg/ml) or B, LY294002 (40µM) in the presence of 
DMSO (0,0389% final concentration in C75-treated cells and 0,1% final concentration in 
LY294002 treated cells) or with the adequate solvent control for 8, 24, 48, 72 hours. Except 
from one untreated sample, all cells were stimulated for 20 minutes with 100ng/ml EGF. 
Cell lysates were collected as described in Materials and Methods for immunoblot 
analysis with antibodies specific for ubiquitin and ß-actin. C, Experiments were quantified 
by using Herolab Software measuring the optical density of each lane relative to the of ß-
actin band. Values of treated samples were then related to those of solvent control 
samples, which have been arbitrarily set at 1 for each individual time point. 
3.4 Changes in gene expression resulting from 
inhibition of FASN 
For gene analysis we used an mRNA array of A2780 FASN-overexpressing 
ovarian cancer cells. Cells were incubated with 7µg/ml C75 or solvent (0,0389% 
DMSO) for 48 hours before total mRNA was isolated. The mRNA gene 
expression array was executed and analyzed by “Kompetenzzentrum für 
Fluoreszente Bioanalytik in Heidelberg” based on standardized and evaluated 
procedures. Genes, which have been modified by C75 at least more than 1,3-
fold or less than 0,7-fold related to the solvent control are designated as up- or 
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downregulated, respectively. Only a short abstract of array-data are shown in 
Table 22. 
Inhibition of FASN affected genes that regulate a variety of biological processes 
including cell proliferation, transcription, apoptosis and degradation are 
presented. We found, that blockade of FASN enhanced the expression of 
several anti-proliferative genes such as CDKN1A (p21) and TP53 (p53) (Table 
22) or inhibited proliferation-promoting genes coding for various cyclins (CCNA2, 
CCNB1, CCND2, CCND1, CCNF) (Table 22) and cyclin-dependent kinases 
(CDK2, CDK10) (Table 22). This coincided with upregulation of several 
apoptosis-enhancing genes such as FAS, some caspase-encoding genes 
(CASP4, CASP8), DAPK1, BAX, the cell surface apoptosis genes ANXA1 and 
ANXA4 and the death receptors TNFRSF10B (TNF-related apoptosis-inducing 
ligand (TRAIL) receptor) and TNFRSF10D (Table 22). Moreover, our results 
demonstrate that the inhibition of FASN enhances CPT1, a key enzyme in fatty 
acid ß-oxidation whose increased expression implicates accumulation of pro-
apoptotic signaling molecule ceramide (Table 22). However, compared to our 
Real Time PCR data the increased expression of CDH1 and CDKN2B could not 
be confirmed by this array (Figure 19, Figure 21, Table 22). In three independent 
biological experiments with C75 treated A2780 cells we showed a significant 5,9-
fold increase of mRNA expression of DAP kinase by Real Time PCR whereas 
this array only showed an impaired effect of C75 on DAP kinase gene 
expression of 1,4-fold augmentation after 48 hours of treatment (Figure 22, Table 
22). Correspondingly, stimulation of SOD2 could not be shown that strongly by 
the mRNA array analysis (1,2-fold) than by Real Time PCR (2,0-fold) after 48 
hours of C75 treatment (Figure 24, Table 22). Strong enhancement in gene 
expression of apoptosis-associated FAS was achieved by FASN inhibition in 
both gene expression assays (Figure 23, Table 22).  
Another effect of FASN inhibition is the regulation of enzymes involved in protein 
ubiquitination. We found that 48 hours incubation with C75 altered not only the 
expression of several E2 ubiquitin conjugating enzymes (UBE2Q1, UBE2D1) but 
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also the expression of the cysteine protease ATG4A, whose activity is induced 
by reactive oxygen species (ROS; especially via H2O2) and is responsible for 
autophagosomal protein degradation in the cell (Shouval et al., 2007). Moreover, 
the gene expression of PSMC4 and PMSC6 (26S proteasome subunits) were 
also enhanced by FASN inhibition (Table 22). These results confirm 
posttranslational effects in ovarian tumor cells caused by FASN blockade, which 
is in accordance with our data shown above (Figure 33, Figure 34). 
Abrogation of FASN leads to widespread changes in metabolism. In A2780 
lipogenesis is affected by FASN inhibition caused by C75. After 48 hours of 
treatment with C75 malonyl-CoA accumulation in the cell possibly leads to 
modulation of ACACA, ACSL1, ACLY and FASN (Table 22). Besides changes in 
fatty acid metabolism, C75 modulates genes extending to pathways other than 
fatty acid metabolism. Inhibition of FASN impaired both the glycolysis and the 
gluconeogenesis, which could be shown by downregulation of LDHC, HK2 and 
PDK1 (Table 22). This suggests that inhibition of FASN may restrict the ability of 
tumor cells to produce the energy necessary to proliferate. 
While the transcription of PI3K cascade signaling molecules (AKT1, AKT2, 
AKT3, FRAP1, RPS6KB1, EIF4EBP1) was slightly impaired and gene 
expression of mTOR-inhibitor (TSC1) was slightly enhanced, our data show a 
compensatory upregulation of MAP kinase survival pathways (MAPK11, 
MAPKAP1) (Table 22). Similar compensatory effects were already shown above 
on protein level in C75-treated A2780, when the specific phosphorylation levels 
of AKT, mTOR and p70S6K were reduced while the specific phosphorylation 
level of ERK1/2 was enhanced after 48 hours incubation (Figure 31B). 
FASN inhibition also affects transcription. Some modulations in expression of 
transcription factors are shown in Table 22. In A2780 cells, JUNB is upregulated 
after 48 hours of incubation with C75, but its translation is reported to be 
controlled via mTOR (Vesely et al., 2009). Gene expression of FOXO3 which is 
known to be involved in apoptosis induction or cell-cycle arrest by transcription of 
related genes (Katayama et al., 2008) is also enhanced by FASN inhibition 
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(Table 22). Blocking of FASN also results in modulation of epigenetic active 
enzymes. In contrast to real time PCR, this array did not show an increase in 
HDAC2 and DNMT3a gene transcription (Figure 26, Figure 28, Table 22) after 
48 hours of incubation with C75. However, similar results in real time PCR and 
array analysis were obtained after 48 hours of incubation concerning the 
downregulation of DNMT1 and DNMT3b (Figure 25, Figure 27, Table 22). In 
conclusion, this short abstract of array data (Table 22) provides only a small 
insight into the comprehensive database of genomic changes that occur in 
response to FASN inhibition. Nevertheless, these array data confirm that FASN 
is central not only for tumor cell metabolism, but also for tumor cell signaling. 
 
Protein Symbol Gene Classication - Description 
Fold 
change 
    
Tumor Suppressor 
Genes 
  
    
not significantly changed   
    
p18 CDKN2C Cyclin-dependent kinase inhibitor 2C 0.84
p16 CDKN2A Cyclin-dependent kinase inhibitor 2A 0.93
E-Cadherin CDH1 Cadherin 1, E-cadherin 1.01
p27 CDKN1B Cyclin-dependent kinase inhibitor 1B 1.06
p15 CDKN2B Cyclin-dependent kinase inhibitor 2B 1.20
PTEN PTEN Phosphatase and tensin homolog 1.25
p19 CDKN2D Cyclin-dependent kinase inhibitor 2D 1.26
p57 CDKN1C Cyclin-dependent kinase inhibitor 1C 1.28
   
upregulated    
    
DAP kinase DAPK1 Death-associated protein kinase 1 1.41
p53 TP53 Tumor protein p53 1.60
MDM2  MDM2 Mdm2 p53 binding protein homolog 3.23
p53INP1 TP53INP1 Tumor protein p53 inducible nuclear protein 1 3.51
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Protein Symbol Gene Classication - Description 
Fold 
change 
   
p53IP3 TP53I3 Tumor protein p53 inducible protein 3 4.37
p21 CDKN1A Cyclin-dependent kinase inhibitor 1A 6.18
    
Proliferation/Cell Cycle   
    
not significantly changed   
    
CCND2  CCND2 Cyclin D2 0.73
CCND1  CCND1 Cyclin D1 0.76
CCNE2  CCNE2 Cyclin E2 0.76
CDK9  CDK9 Cyclin-dependent kinase 9 0.81
CDK4  CDK4 Cyclin-dependent kinase 4 0.82
CDK3  CDK3 Cyclin-dependent kinase 3 0.92
CDK5  CDK5 Cyclin-dependent kinase 5 0.95
CDK7  CDK7 Cyclin-dependent kinase 7 1.22
CDK8  CDK8 Cyclin-dependent kinase 8 1.26
CDK6  CDK6 Cyclin-dependent kinase 6 1.32
    
downregulated    
    
CDK2  CDK2 Cyclin-dependent kinase 2 0.68
CDK10  CDK10 Cyclin-dependent kinase 10 0.63
BRCA1  BRCA1 Breast cancer 1, early onset 0.55
SKP2  SKP2 S-phase kinase-associated protein 2 (p45) 0.50
CCNF  CCNF Cyclin F 0.37
CDC2  CDC2 Cell division cycle 2, G1 to S and G2 to M 0.34
CCNA2  CCNA2 Cyclin A2 0.33
CCNB1  CCNB1 Cyclin B1 0.30
CDCA2  CDCA2 Cell division cycle associated 2 0.25
 
Signaling Molecules 
  
    
not significantly changed   
    
EGFR  EGFR Epidermal growth factor receptor 1.03
ERBB2  ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 0.95
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Protein Symbol Gene Classication - Description 
Fold 
change 
    
ERBB3  ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 1.00
ERBB4  ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 0.79
AKT1  AKT1 v-akt murine thymoma viral oncogene homolog 1 0.73
AKT2  AKT2 v-akt murine thymoma viral oncogene homolog 2 0.79
AKT3  AKT3 
v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, 
gamma) 
0.77 
mTOR FRAP1 FK506 binding protein 12-rapamycin associated protein 1 0.78
TSC1  TSC1 Tuberous sclerosis 1 1.21
TSC2  TSC2 Tuberous sclerosis 2 1.07
p70S6K RPS6KB1 Ribosomal protein S6 kinase, 70kDa, polypeptide 1 0.83
p70S6K RPS6KB2 Ribosomal protein S6 kinase, 70kDa, polypeptide 2 0.98
MAPK1  MAPK1 Mitogen-activated protein kinase 1 1.00
BRAF  BRAF v-raf murine sarcoma viral oncogene homolog B1 1.29
ARAF  ARAF v-raf murine sarcoma 3611 viral oncogene homolog 0.76
RAF1  RAF1 v-raf-1 murine leukemia viral oncogene homolog 1 0.92
    
upregulated    
    
MAPKAP1  MAPKAP1 Mitogen-activated protein kinase associated protein 1 1.41
MAPK11  MAPK11 Mitogen-activated protein kinase 11 1.54
    
downregulated    
    
eIF4eBP1 EIF4EBP1 Eukaryotic translation initiation factor 4E binding protein 1 0.57
    
Protein 
Degradation 
   
    
upregulated    
   
26S proteasome PSMC6 Proteasome (prosome, macropain) 26S subunit, ATPase, 6 1.31
UBE2D1  UBE2D1 Ubiquitin-conjugating enzyme E2D 1 (UBC4/5 homolog, yeast) 1.40
26S proteasome PSMC4 Proteasome (prosome, macropain) 26S subunit, ATPase, 4 1.47
UBE2Q1  UBE2Q1 Ubiquitin-conjugating enzyme E2Q family member 1 1.65
ATG4A  ATG4A ATG4 autophagy related 4 homolog A (S. cerevisiae) 2.10
MDM2 MDM2 Mdm2 p53 binding protein homolog (mouse) 3.23
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Protein Symbol Gene Classication - Description 
Fold 
change 
    
downregulated    
UBE2S  UBE2S Ubiquitin-conjugating enzyme E2S 0.51
UBE2S  UBE2S OK/SW-cl.73 mRNA for ubiquitin carrier protein, complete cds. 0.51
UBE2T  UBE2T Ubiquitin-conjugating enzyme E2T (putative) 0.40
UBE2C  UBE2C Ubiquitin-conjugating enzyme E2C 0.34
    
Apoptosis    
    
not significantly changed   
    
Caspase 2 CASP2 Caspase 2, apoptosis-related cysteine peptidase 0.75
BNIP3  BNIP3 
BCL2/adenovirus E1B 19kDa interacting protein 3, nuclear gene 
encoding mitoch. Protein 
0.78 
Caspase 7 CASP7 Caspase 7, apoptosis-related cysteine peptidase 0.89
Caspase 3 CASP3 Caspase 3, apoptosis-related cysteine peptidase 1.06
DDIT4  DDIT4 DNA-damage-inducible transcript 4 1.11
Caspase 1 CASP1 
Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta,    
convertase) 
1.16 
Caspase 5 CASP5 Caspase 5, apoptosis-related cysteine peptidase 1.28
Caspase 6 CASP6 Caspase 6, apoptosis-related cysteine peptidase 1.28
   
upregulated    
   
DAP kinase DAPK1 Death-associated protein kinase 1 1.41
Caspase 4 CASP4 Caspase 4, apoptosis-related cysteine peptidase 1.52
BAX BAX BCL2-associated X protein 1.62
Caspase 8 CASP8 Caspase 8, apoptosis-related cysteine peptidase 1.79
ANXA1  ANXA1 Homo sapiens annexin A1 1.86
AVEN  AVEN Apoptosis, caspase activation inhibitor 2.00
TNFRSF10D  TNFRSF10D 
Homo sapiens tumor necrosis factor receptor superfamily, member  
10d 
2.41 
GADD45B  GADD45B Growth arrest and DNA-damage-inducible, beta 2.55
TNFRSF10B  TNFRSF10B Homo sapiens tumor necrosis factor receptor superfamily, member 10b 2.62
GADD45A  GADD45A Growth arrest and DNA-damage-inducible, alpha 2.81
FAS FAS Fas (TNF receptor superfamily, member 6) 4.03
ANXA4  ANXA4 Homo sapiens annexin A4 7.45
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Protein Symbol Gene Classication - Description 
Fold 
change 
    
Epigenetically active enzymes  
   
not significantly changed   
    
HDAC2  HDAC2 Histone deacetylase 2 0.82
DNMT3A  DNMT3A DNA (cytosine-5-)-methyltransferase 3 alpha 0.86
    
downregulated    
    
DNMT1  DNMT1 DNA (cytosine-5-)-methyltransferase 1 0.57
DNMT3B  DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta 0.55
 
Metabolism 
   
    
not significantly changed   
    
LDHA LDHA Lactate dehydrogenase A 0.74
NOX4  NOX4 NADPH oxidase 4 0.75
HIF1A  HIF1A Hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix TF) 0.77
Catalase CAT Catalase 0.85
Lyase ACLY ATP citrate lyase 0.87
LDHB  LDHB Lactate dehydrogenase B 0.94
HIF3A  HIF3A Hypoxia inducible factor 3, alpha subunit 1.03
NOX1  NOX1 NADPH oxidase 1 1.10
MnSOD SOD2 
Superoxide dismutase 2, mitochondrial, nuclear gene encoding  mitoch. 
protein 
1.15 
NOX3  NOX3 NADPH oxidase 3 1.18
CPT1 CPT1B 
Carnitine palmitoyltransferase 1B (muscle) , nuclear gene encoding 
mitoch. protein 
1.26 
HIF1AN  HIF1AN Hypoxia-inducible factor 1, alpha subunit inhibitor 1.28
    
upregulated    
   
CPT1C CPT1C Carnitine palmitoyltransferase 1C 1.50
ACSL1  ACSL1 Acyl-CoA synthetase long-chain family member 1 2.11
CPT1A CPT1A 
Carnitine palmitoyltransferase 1A (liver), nuclear gene encoding mitoch. 
protein 
3.90 
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Protein Symbol Gene Classication - Description 
Fold 
change 
   
downregulated    
   
LDHC LDHC Lactate dehydrogenase C 0.64
ACACA ACACA Acetyl-Coenzyme A carboxylase alpha 0.59
FASN FASN Fatty acid synthase 0.54
Lyase CLYBL Citrate lyase beta like 0.43
Hexokinase HK2 Hexokinase 2 0.38
PDK1  PDK1 
Pyruvate dehydrogenase kinase, isozyme 1, nuclear gene encoding 
mitoch. protein 
0.21 
    
Transcription    
    
upregulated    
   
ATF4  ATF4 Activating transcription factor 4 (tax-responsive enhancer element B67) 1.33
FOXO3 FOXO3 Forkhead box O3 1.54
JUNB  JUNB Jun B proto-oncogene (JUNB), mRNA. 2.06
   
downregulated    
    
SREBF1  SREBF1 Sterol regulatory element binding transcription factor 1 0.44
E2F8  E2F8 E2F transcription factor 8 0.36
    
Housekeeping Genes   
    
not significantly changed   
   
GAPDH  GAPDH Glyceraldehyde-3-phosphate dehydrogenase 0.98
ACTB  ACTB Actin, beta 0.80
Table 22: mRNA gene expression array  
was executed and analyzed by “Kompetenzzentrum für Fluoreszente Bioanalytik in 
Heidelberg”. Cells were incubated with 7µg/ml C75 or solvent (0,0389% DMSO) for 48 
hours before total mRNA was isolated. Genes which have been modified by C75 at least 
more than 1,3-fold or less than 0,7-fold related to the solvent control are designated as up- 
or downregulated, respectively. Only a short abstract of array-data are shown in Table 22. 
 
 Discussion 
 105 
4 Discussion 
Unscheduled proliferation in tumor cells frequently results as a consequence of 
hyperactivation of cell-cycle regulating cyclin-dependent kinases (Cdks) through 
amplification or mutation or through overexpression of cyclins and, more 
frequently, inactivation of Cdk inhibitors (Malumbres et al., 2001). In fact, 
inactivation of Cdk inhibitors is a frequent oncogenic alteration in several tumor 
types and both p15INK4b and p16INK4a proteins are inhibitors of Cdks that prevent 
the cell from going through the G1-S phase transition. Therefore, inactivation of 
p15INK4b and p16INK4a is thought to be an important step in cancer development 
(Herman et al., 1996). It is well documented that a proportion of ovarian 
carcinomas harbor p15INK4b methylation (≤33%) or p16INK4a methylation (≤19%) 
and that CpG island methylation is associated with transcriptional silencing of the 
tumor suppressor genes (Liu et al., 2,  2005; Rojas et al., 2009; Katsaros et al., 
2004; Tam et al., 2007). In our experiments, in FASN inhibited A2780 cells 
enhanced expression of p15INK4b is more pronounced at the mRNA than at the 
protein level and actually cannot have further implication on the cell cycle as the 
protein level of p15INK4b is even reduced in C75 treated A2780 (Figure 19, Figure 
31A). A p15INK4b hypermethylated phenotype in ovarian cancer has often been 
reported (Collins et al., 2006; Liu et al., 1, 2005) but we could not show this 
methylation status for the promoter gene of p15INK4b in the cell line A2780 (Figure 
29). It is reported that inhibition of PI3K by LY294002 leads to G1 arrest in 
human ovarian cancer cells through p16INK4a regulation by 
PI3K/AKT/mTOR/p70S6K signaling (Gao et al., 2004). However, in A2780 cells 
mRNA transcription of p16INK4a was neither stimulated by C75 nor by LY294002 
treatment which suggests that the cyclin dependent kinase inhibitor p16INK4a is 
not responsible for cell cycle blockade in G1, neither. In colon carcinoma and 
hepatocellular carcinoma cells FASN blockade causes inhibition of DNA 
replication by blockade of the cell cycle in G1 (Li et al., 2001; Gao et al., 2006). 
 Discussion 
 106 
However, our data suggest that in A2780 ovarian carcinoma cells this C75-
induced cell-cycle arrest is caused through various molecular mechanisms that 
may involve other cyclin dependent kinase inhibitors than p15INK4b or p16INK4a. 
Interestingly, due to C75 treatment we found a significant augmentation of p21 
(CDKN1A) expression in A2780 (Table 22). This cyclin dependent kinase 
inhibitor is known to block cyclin A (CCNA) and cyclin-depedent kinase 2 
(CDK2), which are proliferation promoting factors that are also transcriptionally 
downregulated by FASN inhibition in A2780 cells (Table 22). Maybe massive 
augmentation of p21 could also be responsible for cell-cycle arrest caused by 
FASN inhibition in A2780 tumor cells. Moreover, p21 has been shown to play a 
major role in inducing p53-dependent G1 cell-cycle arrest following DNA damage 
resulting in Cdk inactivation (Malubres et al., 2003). Notably, in A2780 tumor 
cells FASN inhibition caused by C75 increased p53 gene expression, which also 
indicates blockade of S-phase entry by p21 in these cells. Furthermore, it has 
been reported that in normal cells retinoblastoma (Rb) proteins repress the 
transcription of genes required for DNA replication or mitosis through 
sequestering of E2F transcription factors and therefore maintain cells in a 
quiescent state (Attwool et al.,  2004). Upon stimuli, cyclins are normally 
activated and induce cyclin-depedent kinases Cdk4 and Cdk6. Cyclin D-Cdk4/6 
complexes then phosphorylate and inactivate Rb protein, allowing the expression 
of E2F target genes triggering massive transcription of genes required for DNA 
replication and mitosis (Malumbres et al., 2001). Interestingly, in our experiments 
FASN inhibition massively impairs mRNA expression of E2F8 transcription 
factor, even though the cells have been stimulated with 100ng/ml EGF for 
20minutes before lysis and mRNA isolation (Table 22). Maybe this E2F 
transcriptional downregulation could also account for the possible cell-cycle 
arrest caused by FASN inhibition in A2780 carcinoma cells. Additionally, FOXO3 
(Forkhead box O) transcription factor mRNA expression was enhanced by C75 
treatment in A2780 (Table 22). FOXOs are direct targets of AKT phosphorylation 
and are negatively regulated by AKT (Brunet et al., 1999 C). AKT-dependent 
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phosphorylation of FOXOs results in their cytoplasmatic localization and inability 
to exhibit their gene transcriptional activity. FOXOs are reported to be involved in 
apoptosis induction or cell-cycle arrest by transcription of related genes 
(Medema et al.,  2000). Our results suggest that augmentation in FOXO3 gene 
expression (Table 22) and reduced AKT activity (Figure 31B) both caused by 
FASN inhibition could also be associated with potential cell-cycle arrest in A2780 
tumor cells. Besides possible C75-induced cell-cycle arrest in tumor cells 
abrogation of FASN also leads to widespread changes in metabolism, which 
often induces apoptosis in these cells (Bandyopadhyay et al., 2006). FASN 
inhibition causes accumulation of its substrate malonyl-CoA. The activity of 
carnitine palmitoyltransferase 1 (CPT1), which regulates ß-oxidation of fatty 
acids is blocked by malonyl-CoA. Hence, inhibited CPT1 induces sphingolipid 
ceramide accumulation, which then provokes ceramide-mediated mitochondrial 
apoptotic pathway induction as the enhanced transcription of DAP kinase mRNA 
in our results approves (Figure 22, Table 22) (Bandyopadhyay et al., 2006). 
Moreover, our mRNA array data of C75 treated A2780 show an increase in 
mRNA expression level of CPT1 (Table 22), which confirms this effect too 
(Menendez et al., 2007). Furthermore, CPT1 was co-immunoprecipitated with 
BCL-2 suggesting a physical association between CPT1 and the mitochondrial 
apoptotic apparatus (Paumen et al., 1997). In our experiments the increased 
mRNA levels of TNF-α-associated FAS, TNFRSF10B and TNFRSF10D (Figure 
23, Table 22) suggest that FASN blockade in A2780 ovarian carcinoma cells 
also elevates TNF-α-associated apoptosis. Similar effects caused by FASN 
inhibition were reported in breast cancer cells (Bandyopadhyay et al., 2006). 
Additionally, our mRNA array data of C75 treated A2780 cells show an increase 
in transcription of p53 gene initiating growth arrest or enhanced apoptosis (Table 
22). FASN is not only important for phospholipid synthesis of the outer cell 
membrane but also for inner membranes such as the endoplasmatic reticulum 
(ER) membrane. Furthermore, FASN activity drives phospholipid synthesis, 
which primarily occurs in the ER (Swinnen et al., 2003). Because of the direct 
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connection between FASN activity and phospholipid synthesis, FASN blockade 
results in ER stress response in a variety of tumor cells, but not in normal cells 
(Little et al., 2007). Indeed, FASN inhibition has even been shown to cooperate 
with ER stress inducer to induce cell death by increased unfolded protein 
response (UPR) signaling (Little et al., 2008). Accordingly, our array data show 
an augmentation of ATF4 and GADD45A and GADD45B mRNA expression, 
which are canonical markers of the endoplasmatic reticulum (ER) stress 
response in tumor cells caused by FASN blockade. For instance, it is known that 
ATF4 acts to protect the cells from ER-generated reactive oxygen species (Little 
et al., 2007) indicating that ER-stress could also play a role in programmed cell 
death induced by FASN inhibition in A2780 cells. All these data suggest that 
FASN inhibition in tumor cells enhances programmed cell-death via several 
pathways. In this work we could confirm TNFα-associated, nuclear, ER- and 
mitochondrial stress induced apoptosis in FASN inhibited A2780 ovarian cancer 
cells. Besides the already discussed apoptotic effects of FASN inhibition, FASN 
blockade entails accumulation of NADPH that activates NADPH-oxidase (NOX) 
thus causing formation of reactive oxygen species (ROS), which in turn 
stimulates the detoxification activity of MnSOD (Menendez et al., 2007). MnSOD 
catalyzes the reaction of O2 to H2O2, which is then catalyzed to H2O and O2 by 
catalase. While we could show an increase of mRNA level of the antioxidant 
enzyme MnSOD caused by FASN blockade (Figure 24, Table 22) in both Real 
Time PCR and micro array experiments, we could not show any augmentation of 
catalase in our mRNA array of C75 treated A2780 (Table 22). Hence, there is the 
possibility that H2O2 is not finally cleaned up in the cells after C75 treatment has 
induced oxidative stress in the cells. However, a conclusive molecular 
explanation of the anti-proliferative and death promoting effects of FASN-
inhibitors is still missing. Moreover, recent findings suggest that ROS production 
can lead to modulation of methylation of the CDH1 gene promoter (Lim et al., 
2008). 
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It is shown that in a proportion of ovarian carcinomas aberrant promoter 
methylation of CDH1 gene (≤42%) is detected and that methylation status of 
CDH1 is closely associated with the decrease of E-Cadherin protein expression 
(Yuecheng et al., 2006). Interestingly, in A2780 cells C75 and LY294002 
increase E-Cadherin mRNA expression level in Real Time PCR indicating that 
both compounds can modulate the adhesion specificity and maybe can improve 
targeting invasion and metastases in ovarian carcinoma (Yuecheng et al., 2006). 
If demethylating effects of C75 or LY294002 result in enhanced CDH1 mRNA 
expression in A2780 cells remains unclear. 
Several types of tumors, including ovarian cancer, are known to have a 
hypermethylation phenotype (Esteller et al., 2001; Strathdee et al., 2001). 
Especially, DAP kinase methylation is observed in 67% of patients with 
malignant ovarian carcinomas (Collins et al., 2006). Our results also show a 
hypermethylated status in the DAP kinase gene in solvent treated A2780 cells. 
After C75 treatment, the level of methylated DNA in the DAP kinase gene was 
decreased (Figure 30). Therefore, we hypothesize that the upregulation of DAP 
kinase mRNA expression level by FASN blockade, which could be shown by 
both Real Time PCR and array (Figure 22, Table 22), is caused by 
demethylating effects of C75 targeting DAP kinase gene. Until now the 
relationship between the FASN biochemical pathway and the epigenetic 
regulation of tumor suppressor genes has been completely unexplored. The 
present study is the first report about epigenetic effects caused by FASN 
inhibition in ovarian carcinoma cells. Accordingly, we investigated whether 
modulation of gene expression levels of epigenetic active enzymes might also 
occur by blocking of FASN. Unlike DNMT3a, which was increased in its mRNA 
level (Figure 26), DNMT3b and DNMT1 mRNA transcription levels were shown 
to be decreased by C75-caused FASN inhibition by both Real Time PCR and 
array (Figure 25, Figure 27, Table 22). This downregulation of DNMTs suggests 
a transcription-activating effect on the genome and would correlate with the 
increased DAP kinase gene demethylation and the increased mRNA expression 
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if its gene after FASN blockade in A2780 cells. Interestingly, in our experiments 
gene expression of HDAC2 could not be impaired by C75 treatment but was 
even shown to be enhanced by Real Time PCR analysis (Figure 28). It is well 
known that epigenetic transcriptional gene silencing is characterized by a 
hypermethylated and hypoacetylated phenotype (Esteller et al., 2007). Thus, on 
the one hand our results indicate a transcriptional activation by downregulation of 
DNMTs (DNMT1, DNMT3b) mRNA levels but on the other hand our results 
suggest a transcriptional silencing by augmentation of HDAC2 mRNA expression 
level. Moreover, our mRNA array data of C75 treated A2780 show an increase in 
mRNA expression level of CPT1 (Table 22). Recently, a new role of CPT1 in 
histonic acetylation levels of tumors and cancer development was proposed, 
because CPT1 proteins and HDAC1 were co-immunoprecipitated in nuclear 
extracts from neoplastic MCF-7 cells (Mazzarelli et al., 2007). In this paper the 
authors identified a new role of CPT1 in addition to the physiological role in the 
transport of long-chain fatty acids into mitochondria and showed that CPT1 plays 
a role in histone acetylation status of tumor cells (Mazzarelli et al., 2007). Maybe 
in A2780 the C75-enhanced CPT1 also builds complexes with C75-induced 
HDACs leading to their nuclear import and genome hypoacetylation in these 
cells. Furthermore, our array data of C75 treated A2780 suggest, that citrate 
lyase (CLYBL), which converts glucose-derived citrate into acetyl-CoA is 
markedly decreased (Table 22). As citrate lyase is required for histone 
acetylation (Wellen et al., 2009) this effect of FASN inhibition could also result in 
a hypoacetylated phenotype in A2780 cells. In A2780 tumor cells the increase in 
HDAC2 and CPT1 mRNA expression levels and the decrease of citrate lyase 
gene expression level could support deacetylating effects caused by FASN 
inhibition. Accordingly, upregulation of DNMT3a gene expression level by FASN 
blocking could be a further response to the transcriptional silencing action of C75 
in A2780 carcinoma cells. However, our array data also show a downregulation 
of acetyl-CoA carboxylase (ACACA) mRNA level and a significant augmentation 
of acetyl-CoA synthetase gene expression due to FASN inhibition (Table 22), 
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which indicates accumulation of acetyl-CoA in C75-treated A2780 cells. 
Therefore, we hypothesize that the increased HDAC2 transcription could also be 
a counteraction against accumulated acetyl-CoA in A2780 cells caused by FASN 
blockade. In general, the entire epigenetic machinery targets not only specifically 
to tumor suppressor genes and the modulation of DNMTs or HDACs mRNA 
expression levels gives us just very indecisive information about their epigenetic 
activities (Esteller et al., 2007). Nevertheless, this study is the first report about 
epigenetic effects caused by FASN inhibition in ovarian carcinoma cells and it 
argues for epigenetic mechanism of action of the FASN blocking drug C75 – 
although it is likely that many effects are the consequence of secondary 
mechanisms. 
Phosphatidylinositol 3-kinase (PI3K) activity in ovarian cancer cells is well known 
to be required for the cell proliferation and G1 cell cycle progression. Recent 
studies indicate that the gene encoding the catalytic subunit of PI3K is amplified 
in ≤40% of primary ovarian carcinoma cells as well as in several ovarian 
epithelial cancer cell lines (Gao et al., 2004; Katayama et al., 2008). Modulation 
of the PI3K/AKT signaling pathway by FASN Inhibition in ovarian carcinoma cell 
lines has already been observed (Grunt et al., 2009; Wang et al., 2005). Of note, 
phospholipid endproducts of FASN action are incorporated into cell membranes 
and form lipid rafts, which accommodate ErbB receptors. Inhibition of FASN 
decreases these lipid rafts and impedes recruitment and phosphorylation of 
downstream mediators such as AKT (Grunt et al., 2009). Interestingly, another 
recent report suggests that ROS evokes an AKT conformational change by 
forming intramolecular disulfide bonds, which results in disruption of AKT-HSP90 
binding and enhancement of AKT-PP2A interaction and dephosphorylation at 
Ser 473 (Cao et al., 2009). In our experiments we obtained reduction of total 
protein expression levels (Figure 31A) and impaired phosphorylation levels of 
AKT, mTOR, p70S6K, p15 and 4eBP1 (Figure 31B) through treatment of the 
A2780 cells with the FASN inhibiting drug C75. Interestingly, C75 inhibits AKT, 
mTOR, p70S6K and 4eBP1 phosphorylation caused by EGF stimulation 
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(100ng/ml) and simultaneously decreases their total protein levels. In contrast, 
phospho-ERK1/2 levels increase slightly upon C75 treatment in A2780, even 
though total ERK1/2 protein expression also slightly declines at later time points 
of exposure (Figure 31A, B). Enhancement of ERK1/2 phosphorylation is also 
observed in LY294002 treated A2780 ovarian cancer cells (Figure 32A, B). 
Unlike FASN inhibition by C75, the PI3K inhibitor LY294002 does not remarkably 
lower the total protein levels of several proteins involved in PI3K/AKT signaling. 
These data indicate that C75-mediated blockade of FASN reduces the activity of 
the PI3K cascade and concurrently slightly activates ERK1/2 in A2780, which 
supports the findings that phospho-AKT negatively regulates the MAPK cascade 
e.g. by curbing Raf-1 function (Hennessy et al.,  2005) or by the proximal mTOR 
activator Rheb that has been implicated in the direct interaction and inhibition of 
B-Raf and Raf1 (Karbowniczek et al., 2006). In our experiments C75 seems to 
decrease the total protein level of all analyzed signal proteins of the PI3K 
cascade, while LY294002 rather leaves the total protein levels unchanged or 
even augments the total protein levels of the PI3K cascade molecules. A recent 
study in breast cancer indicates that FASN inhibition enhances DDIT4 (DNA 
damage inducible transcript 4), a stress response gene that negatively regulates 
mTOR pathway, which controls protein biosynthesis through activation of 
translation initiation factor eIF4E and induces caspase-8-mediated tumor cell 
apoptosis (Knowles et al., 2008). In our mRNA array data we could not obtain a 
significant increase of DDIT4 gene expression but caspase-8 gene expression 
level was enhanced (Table 22). Another study suggests that FASN inhibition 
causes ER stress and activates unfolded protein response in tumor cells (Little et 
al., 2007). Interestingly, the authors could show that several indicators of ER 
stress and inhibition of protein synthesis were detected before caspase 3 and 
PARP cleavage, the hallmarks of apoptosis (Little et al., 2007). Maybe FASN 
inhibition leads to apoptosis and protein degradation through ER stress and 
unfold protein response in A2780 cells, too.  
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Under normal cellular conditions, eIF4F translation complex assembly is limited 
as eIF4E is sequestered from eIF4G by binding to eIF4eBP1 (4eBP1). 
Stimulation of the PI3K/AKT/mTOR signaling then normally leads to 4eBP1 
phosphorylation, dislodging 4eBP1 from eIF4E and enabling assembly of the 
eIF4F complex (Graff et al., 2008). However, we could exclude that the 
dephosphorylation of 4eBP1 and therefore the decreased eIF4F complex 
formation and translation is the reason for protein level reduction of AKT, mTOR, 
p70S6K, 4eBP1 and ERK1/2 by FASN inhibition in A2780 because incubation 
with LY294002 totally abrogates phosphorylation of 4eBP1 without affecting 
protein levels of these proteins (Figure 32A, B). Therefore, we assume that 
translation inhibition by unphosphorylated 4eBP1 does not influence translation 
of the analyzed proteins. We then investigated whether proteasomal degradation 
is responsible for decrease in protein levels. Enhanced degradation was 
obtained in all analyzed proteins caused by C75 while translation was inhibited 
by Cycloheximide. Especially, the strong degradation of p15INK4b protein lets us 
hypothesize that this post-translational modification caused by C75 compensates 
the high increase in mRNA transcription of this gene. Our results show that 
increased post-translational ubiquitination could be the reason for enhanced 
protein degradation (Figure 34). Ubiquitination is an important regulatory post-
translational modification of lysine residues. Polyubiquitination targets proteins 
for degradation via the 26S proteasomal pathway. The multienzyme complexes, 
which mediate protein ubiquitination consist of activating (E1), conjugating (E2), 
and ligating (E3) enzymes (Gwalter et al., 2008). However, ubiquitination-
associated enzymes target their client proteins in a quite non-specific way and 
up to date only one deubiquitinating enzyme has been matched to a specific 
substrate. This is ubiquitin-specific protease 2a (USP2a), which interacts with 
and stabilizes FASN (Graner et al., 2004). Interestingly, a genome-wide analysis 
of changes in MDA-MB-435 tumor cells caused by FASN knockdown, revealed 
significant effects of FASN inhibition on enhanced protein ubiquitination 
(Knowles et al., 2007). Moreover, it has already been reported that the cellular 
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levels of several members of the serine/threonine protein kinases A, G and C 
(AGC kinases) are controlled by polyubiquitination through mechanisms, which 
are independent on activation state or kinase activity (Bogusz et al., 2006). In 
particular, they could show that the protein levels of serum- and glucocorticoid-
induced kinase 1 (SGK1) and ribosomal protein S6 kinase (S6K) are regulated 
by ubiquitination, which controls their steady-state levels (Brickley et al., 2002;  
Wang et al., 2008). One study even suggests that ubiquitin ligases Roc1 and 
MDM2 specifically interact with and induce the ubiquitination of S6K (Gwalter et 
al., 2008). Thus, these studies show that several signaling pathways can be 
regulated by steady-state levels of their signaling proteins next to activation by 
phosphorylation. Even so, a number of studies support a model, whereby 
activation of kinases triggers their own degradation via the ubiquitin-proteasome 
pathway to prevent accumulation of activated kinases in the cells (Lu et al., 
1998). Our results show highest degradation of all analyzed protein after longer 
times of exposure to C75. This coincides with the highest ubiquitination status 
and minimal phosphorylation status of proteins after longer time of treatment with 
the FASN inhibitor C75 (Figure 31, Figure 34). Theses findings indicate that in 
A2780 ovarian cancer cells decrease in protein levels of AKT, mTOR, p70S6K, 
p15INK4b and 4eBP1 is caused by FASN inhibition due to their enhanced 
ubiquitination and proteasomal degradation and independent of their 
phosphorylation. Moreover, in our array data we could show a significant 
increase in MDM2 gene expression level indicating that this ubiquitin ligase could 
also be associated with enhanced degradation caused by C75 treatment. In 
absence of phosphorylation, AKT becomes protected by a molecular chaperone, 
the heat shock protein 90 (Hsp90), from ubiquitination-mediated proteasome 
degradation (Facchinetti et al., 2008). Maybe a combination of C75 and the 
Hsp90 inhibitor 17-AAG would abrogate AKT activation even more effectively 
and potentiate PI3K blockade in ovarian cancer cells. This idea could be a new 
approach to dispose oncogenic AKT activation in tumor cells. Collectively, these 
data show that FASN activity is involved in the functionality of the proteasomal 
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pathway and that there consists a crosstalk between FASN and proteasome 
pathways. This is an important issue on which further investigations should be 
focused. In our mRNA array data we further found that FASN inhibition increases 
the mRNA expression level of ATG4A, which encodes a cysteine protease that is 
ROS, especially H2O2, induced and functions to target proteins for degradation 
by autophagosomal degradation (Shouval et al., 2007). As we could already 
show a possible accumulation of H2O2 in C75-treated A2780 cells (Table 22) this 
indicates that maybe other degradation pathways are also influenced by FASN 
inhibition in A2780 cells. 
In summary, this is the first report about the epigenetic modulating action of the 
FASN inhibitor C75. In this work we further pointed out several effects caused by 
FASN blocking. We could show and confirm anti-proliferative and apoptotic-
inducing effects – among others - induced by demethylation activity, and 
enhanced ubiquitin-mediated degradation of several protein members of the 
PI3K cascade. 
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